



106TH CONGRESS
2D SESSION

S. 2807

To amend the Social Security Act to establish a Medicare Prescription Drug and Supplemental Benefit Program and to stabilize and improve the Medicare+Choice program, and for other purposes.

IN THE SENATE OF THE UNITED STATES

JUNE 28, 2000

Mr. BREAU (for himself, Mr. FRIST, Mr. KERREY, Mr. BOND, Mr. SANTORUM, Ms. LANDRIEU, Mr. ASHCROFT, and Ms. COLLINS) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend the Social Security Act to establish a Medicare Prescription Drug and Supplemental Benefit Program and to stabilize and improve the Medicare+Choice program, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) SHORT TITLE.—This Act may be cited as the
5 “Medicare Prescription Drug and Modernization Act of
6 2000”.

1 (b) TABLE OF CONTENTS.—The table of contents of
 2 this Act is as follows:

Sec. 1. Short title; table of contents.

Sec. 2. Findings and purposes.

TITLE I—MEDICARE MANAGEMENT AND ADMINISTRATION

Subtitle A—Establishment of the Competitive Medicare Agency

Sec. 101. Establishment of the Competitive Medicare Agency.

“TITLE XXII—MEDICARE COMPETITION AND PRESCRIPTION
 DRUGS

“PART A—ESTABLISHMENT OF THE COMPETITIVE MEDICARE AGENCY

“Sec. 2201. Competitive Medicare Agency.

“Sec. 2202. Commissioner; Deputy Commissioner; other officers.

“Sec. 2203. Administrative duties of the Commissioner.

“Sec. 2204. Medicare Competition and Prescription Drug Advisory
 Board.”.

Sec. 102. Commissioner as member of the board of trustees of the medicare
 trust funds.

Sec. 103. Salary increase for the HCFA Administrator.

Subtitle B—Redefined Medicare Solvency Measures

Sec. 151. Requirements for annual financial reporting and oversight of medi-
 care program.

TITLE II—MEDICARE PRESCRIPTION DRUG AND SUPPLEMENTAL
 BENEFIT PROGRAM

Sec. 201. Establishment of program.

“PART B—MEDICARE PRESCRIPTION DRUG AND SUPPLEMENTAL BENEFIT
 PROGRAM

“Sec. 2221. Establishment of Prescription Drug and Supplemental Benefit
 Program.

“Sec. 2222. Enrollment under program.

“Sec. 2223. Election of a Medicare Prescription Plus plan.

“Sec. 2224. Beneficiary information.

“Sec. 2225. Outpatient prescription drug and other supplemental benefits.

“Sec. 2226. Beneficiary protections.

“Sec. 2227. Requirements for entities offering Medicare Prescription Plus
 plans.

“Sec. 2228. Submission of Medicare Prescription Plus plans.

“Sec. 2229. Approval of Medicare Prescription Plus plans.

“Sec. 2230. Payments to Medicare Prescription Plus plans for benefits.

“Sec. 2231. Computation and collection of beneficiary share of premium.

“Sec. 2232. Additional prescription drug subsidies through reinsurance.

“Sec. 2233. Plan fees for administrative costs.

“Sec. 2234. Medicare prescription drug account.

“Sec. 2235. Secondary payer provisions.

- “Sec. 2236. Definitions; treatment of references to provisions in Medicare+Choice program.”.
- Sec. 202. Amendments to Federal Supplementary Medical Insurance Trust Fund.
- Sec. 203. Prescription drug coverage under the Medicare+Choice program.
- Sec. 204. Medicaid amendments.
- “Sec. 1935. Special provisions relating to medicare prescription drug benefit.”.
- Sec. 205. Medigap provisions.
- Sec. 206. GAO report on part B payment for drugs and biologicals and related services.

TITLE III—MEDICARE+CHOICE REFORMS

- Sec. 301. Increase in national per capita Medicare+Choice growth percentage in 2001 and 2002.
- Sec. 302. Removing application of budget neutrality beginning in 2002.
- Sec. 303. Medicare+Choice competition program.
- Sec. 304. Freeze of health risk adjuster at 20 percent.

TITLE IV—MEDICARE BENEFICIARY OUTREACH AND EDUCATION

- Sec. 401. Medicare Consumer Coalitions.

“PART C—MEDICARE CONSUMER COALITIONS

- “Sec. 2281. Establishment of medicare consumer coalitions.”.

1 **SEC. 2. FINDINGS AND PURPOSES.**

2 (a) FINDINGS.—

3 (1) Based on the deliberations of the National
 4 Bipartisan Commission on the Future of Medicare,
 5 the medicare program under title XVIII of the So-
 6 cial Security Act in its current form is
 7 unsustainable, with the part A trust fund scheduled
 8 to become insolvent in 2025.

9 (2) The medicare program relies on general rev-
 10 enues to pay for 36 percent of total program ex-
 11 penditures and will continue to use an increasing
 12 share of general revenues. Part B outlays under
 13 such program, $\frac{3}{4}$ of which are funded through gen-

1 eral revenues, have increased 38 percent over the
2 past 5 years, or about 5 percent faster than the
3 economy as a whole.

4 (3) Medicare's spending, left unchecked, will
5 continue to consume an increasing share of the Fed-
6 eral budget, leaving little room for other priorities,
7 such as defense, education, debt reduction, tax cuts,
8 and domestic spending.

9 (4) Medicare's current benefit package is out-
10 dated in that it does not provide a prescription drug
11 benefit and limits beneficiary access to new tech-
12 nologies.

13 (5) Medicare only covers 53 percent of a bene-
14 ficiary's average health care costs and exposes bene-
15 ficiaries to large out-of-pocket liabilities.

16 (6) The number of beneficiaries in the medicare
17 program is estimated to more than double by the
18 end of 2030, due to the influx of 77,000,000 baby
19 boomers beginning in 2010.

20 (7) Each year there are fewer workers paying
21 payroll taxes to fund current medicare obligations,
22 evidenced by a decrease in the number of workers
23 per retiree from 4.5 in 1960 to 3.9 in 2000. This
24 number is expected to decline further to 2.8 in 2020.

(8) The Balanced Budget Act of 1997 and the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 underscore the need to fundamentally restructure the medicare program and reduce Government micromanagement of that program.

(b) PURPOSES.—The purposes of this Act are—

(1) to improve the Medicare+Choice program by adopting a stable, competitive system that provides medicare beneficiaries with better and broader health coverage and a greater variety of affordable options from which to choose.

(2) to assist all medicare beneficiaries, especially those with low incomes, in obtaining coverage for outpatient prescription drugs;

(3) to establish an independent executive branch Competitive Medicare Agency outside of the Health Care Financing Administration and the Department of Health and Human Services based on the Social Security Administration to administer the outpatient prescription drug benefit and the Medicare+Choice program;

(4) to increase the flexibility of the medicare program and provide medicare beneficiaries timely access to the latest advances in the practice of medi-

1 cine and delivery of care and to end the congres-
 2 sional micromanagement over prices and delivery of
 3 benefits currently administered through approxi-
 4 mately 130,000 pages of rules and regulations estab-
 5 lished under the medicare program; and

6 (5) to better determine the financial health of
 7 the medicare program by establishing a mechanism
 8 that monitors the total spending and revenues of the
 9 medicare program and serves as an early warning
 10 system that triggers congressional debate on policy
 11 decisions and that takes into account recommenda-
 12 tions of the Medicare Competition and Prescription
 13 Drug Advisory Board.

14 **TITLE I—MEDICARE MANAGE-**
 15 **MENT AND ADMINISTRATION**

16 **Subtitle A—Establishment of the**
 17 **Competitive Medicare Agency**

18 **SEC. 101. ESTABLISHMENT OF THE COMPETITIVE MEDI-**
 19 **CARE AGENCY.**

20 (a) IN GENERAL.—The Social Security Act (42
 21 U.S.C. 301 et seq.) is amended by adding at the end the
 22 following new title:

1 “TITLE XXII—MEDICARE COMPETITION AND
2 PRESCRIPTION DRUGS

3 “PART A—ESTABLISHMENT OF THE COMPETITIVE
4 MEDICARE AGENCY

5 “COMPETITIVE MEDICARE AGENCY

6 “SEC. 2201. (a) ESTABLISHMENT.—There is estab-
7 lished, as an independent agency in the executive branch
8 of the Government, a Medicare Competition Agency (in
9 this part referred to as the ‘Agency’).

10 “(b) DUTY.—

11 “(1) IN GENERAL.—It shall be the duty of the
12 Agency to administer the Medicare Prescription
13 Drug and Supplemental Benefit Program under part
14 B of this title and the Medicare+Choice program
15 under part C of title XVIII.

16 “(2) TRANSITION.—The Secretary of Health
17 and Human Services (in this title referred to as the
18 ‘Secretary’), the Commissioner of the Competitive
19 Medicare Agency, and the Administrator of the
20 Health Care Financing Administration shall estab-
21 lish an appropriate transition of responsibility in
22 order to redelegate the administration of part C
23 from the Secretary and the Administrator of the
24 Health Care Financing Administration to the Com-

missioner as is appropriate to carry out the purposes
of this section.

3 “(3) CONSTRUCTION.—Insofar as a responsi-
4 bility of the Secretary or the Administrator of the
5 Health Care Financing Administration is redele-
6 gated to the Commissioner of the Competitive Medi-
7 care Agency under this part, any reference to the
8 Secretary or the Administrator of the Health Care
9 Financing Administration in this title or title XI
10 with respect to such responsibility is deemed to be
11 a reference to such Commissioner.

12 “COMMISSIONER; DEPUTY COMMISSIONER; OTHER

13 OFFICERS

14 “SEC. 2202. (a) COMMISSIONER OF THE COMPETI-
15 TIVE MEDICARE AGENCY.—

16 “(1) APPOINTMENT.—There shall be in the
17 Agency a Commissioner of the Competitive Medicare
18 Agency (in this part referred to as the ‘Commis-
19 sioner’) who shall be appointed by the President, by
20 and with the advice and consent of the Senate.

21 “(2) COMPENSATION.—The Commissioner shall
22 be compensated at the rate provided for level I of
23 the Executive Schedule.

24 “(3) TERM.—

25 “(A) IN GENERAL.—The Commissioner
26 shall be appointed for a term of 6 years.

1 “(B) CONTINUANCE IN OFFICE.—In any
2 case in which a successor does not take office
3 at the end of a Commissioner’s term of office,
4 such Commissioner may continue in office until
5 the appointment of a successor.

6 “(C) DELAYED APPOINTMENTS.—A Com-
7 missioner appointed to a term of office after the
8 commencement of such term may serve under
9 such appointment only for the remainder of
10 such term.

11 “(D) REMOVAL.—An individual serving in
12 the office of Commissioner may be removed
13 from office only pursuant to a finding by the
14 President of neglect of duty or malfeasance in
15 office.

16 “(4) RESPONSIBILITIES.—The Commissioner
17 shall be responsible for the exercise of all powers
18 and the discharge of all duties of the Agency, and
19 shall have authority and control over all personnel
20 and activities thereof. Responsibilities of the Com-
21 missioner shall include the following:

22 “(A) GENERAL RESPONSIBILITIES.—

23 “(i) ELIGIBILITY AND ENROLL-
24 MENT.—Coordinating determinations of
25 beneficiary eligibility and enrollment under

1 title XVIII and part B of this title with
2 the Commissioner of Social Security.

3 “(ii) CONTRACTING AUTHORITY.—En-
4 tering into, and enforcing, contracts with
5 entities for the offering of Medicare Pre-
6 scription Plus plans under part B of this
7 title.

8 “(iii) DISSEMINATION OF INFORMA-
9 TION.—Conducting information activities
10 under sections 1804 and 1851(d) of title
11 XVIII, and under part B of this title with
12 respect to benefits and limitations on pay-
13 ment under Medicare Prescription Plus
14 plans under part B of this title, including
15 a comparative analysis of such plans and
16 the quality of such plans in the area in
17 which the medicare beneficiary resides.
18 The information disseminated pursuant to
19 such activities shall be presented in a man-
20 ner so that medicare beneficiaries may
21 compare benefits under parts A and B of
22 title XVIII, part B of this title, and medi-
23 care supplemental policies under section
24 1882 with benefits under Medicare+Choice
25 plans under part C of title XVIII.

“(iv) DISSEMINATION OF APPEALS RIGHTS INFORMATION.—Disseminating to medicare beneficiaries a description of procedural rights (including grievance and appeals procedures) of beneficiaries under the original medicare fee-for-service program under parts A and B of title XVIII, the Medicare+Choice program under part C of such title, and the Outpatient Prescription Drug and Supplemental Benefit Program under part B of this title.

“(v) BENEFICIARY EDUCATION PROGRAM.—Establishing a medicare beneficiary education program to provide timely, readable, accurate, and understandable information to medicare beneficiaries regarding Medicare Prescription Plus plan options.

“(B) OTHER RESPONSIBILITIES.—The Commissioner shall carry out any responsibility provided for under part C of title XVIII or part B of this title, including demonstration projects carried out in part or in whole under such parts, the programs of all-inclusive care for the elderly (PACE program) under section 1894,

1 the social health maintenance organization
2 (SHMO) demonstration projects (referred to in
3 section 4104(c) of the Balanced Budget Act of
4 1997), and through a Medicare+Choice project
5 that demonstrates the application of capitation
6 payment rates for frail elderly medicare bene-
7 ficiaries through the use of an interdisciplinary
8 team and through the provision of primary care
9 services to such beneficiaries by means of such
10 a team at the nursing facility involved).

11 “(C) ANNUAL REPORTS.—Not later than
12 March 31 of each year, the Commissioner shall
13 submit to Congress and the President a report
14 on the administration of part C of title XVIII
15 and part B of this title during the previous fis-
16 cal year.

17 “(5) PROMULGATION OF RULES AND REGULA-
18 TIONS.—

19 “(A) IN GENERAL.—The Commissioner
20 may prescribe such rules and regulations as the
21 Commissioner determines necessary or appro-
22 priate to carry out the functions of the Agency.

23 “(B) RULEMAKING.—The regulations pre-
24 scribed by the Commissioner shall be subject to

1 the rulemaking procedures established under
2 section 553 of title 5, United States Code.

3 “(6) DELEGATION OF AUTHORITY.—

4 “(A) IN GENERAL.—The Commissioner
5 may assign duties, and delegate, or authorize
6 successive redelegations of, authority to act and
7 to render decisions, to such officers and employ-
8 ees of the Agency as the Commissioner may
9 find necessary.

10 “(B) EFFECT OF DELEGATION.—Within
11 the limitations of such delegations, redelega-
12 tions, or assignments, all official acts and deci-
13 sions of such officers and employees shall have
14 the same force and effect as though performed
15 or rendered by the Commissioner.

16 “(7) CONSULTATION WITH SECRETARY OF
17 HEALTH AND HUMAN SERVICES.—The Commis-
18 sioner and the Secretary shall consult, on an ongo-
19 ing basis, to ensure—

20 “(A) the coordination of the programs ad-
21 ministered by the Commissioner under part C
22 of title XVIII and part B of this title with the
23 programs administered by the Secretary under
24 parts A and B of title XVIII and under title
25 XIX; and

1 “(B) that adequate information concerning
2 benefits under parts A and B of title XVIII and
3 title XIX is available to the public.

4 “(b) DEPUTY COMMISSIONER OF THE COMPETITIVE
5 MEDICARE AGENCY.—

6 “(1) APPOINTMENT.—There shall be in the
7 Agency a Deputy Commissioner of the Competitive
8 Medicare Agency (in this part referred to as the
9 ‘Deputy Commissioner’) who shall be appointed by
10 the President, by and with the advice and consent
11 of the Senate.

12 “(2) TERM.—

13 “(A) IN GENERAL.—The Deputy Commis-
14 sioner shall be appointed for a term of 6 years.

15 “(B) CONTINUANCE IN OFFICE.—In any
16 case in which a successor does not take office
17 at the end of a Deputy Commissioner’s term of
18 office, such Deputy Commissioner may continue
19 in office until the entry upon office of such a
20 successor.

21 “(C) DELAYED APPOINTMENT.—A Deputy
22 Commissioner appointed to a term of office
23 after the commencement of such term may
24 serve under such appointment only for the re-
25 mainder of such term.

1 “(3) COMPENSATION.—The Deputy Commis-
2 sioner shall be compensated at the rate provided for
3 level II of the Executive Schedule.

4 “(4) DUTIES.—

5 “(A) IN GENERAL.—The Deputy Commis-
6 sioner shall perform such duties and exercise
7 such powers as the Commissioner shall from
8 time to time assign or delegate.

9 “(B) ACTING COMMISSIONER.—The Dep-
10 uty Commissioner shall be Acting Commissioner
11 of the Agency during the absence or disability
12 of the Commissioner, unless the President des-
13 ignates another officer of the Government as
14 Acting Commissioner, in the event of a vacancy
15 in the office of the Commissioner.

16 “(c) CHIEF ACTUARY.—

17 “(1) APPOINTMENT.—

18 “(A) IN GENERAL.—There shall be in the
19 Agency a Chief Actuary, who shall be appointed
20 by, and in direct line of authority to, the Com-
21 missioner.

22 “(B) QUALIFICATIONS.—The Chief Actu-
23 ary shall be appointed from individuals who
24 have demonstrated, by their education and ex-

1 perience, superior expertise in the actuarial
2 sciences.

3 “(C) DUTIES.—The Chief Actuary shall
4 serve as the chief actuarial officer of the Agen-
5 cy, and shall exercise such duties as are appro-
6 priate for the office of the Chief Actuary and
7 in accordance with professional standards of ac-
8 tuarial independence.

9 “(2) COMPENSATION.—The Chief Actuary shall
10 be compensated at the highest rate of basic pay for
11 the Senior Executive Service under section 5382(b)
12 of title 5, United States Code.

13 “ADMINISTRATIVE DUTIES OF THE COMMISSIONER

14 “SEC. 2203. (a) PERSONNEL.—

15 “(1) IN GENERAL.—The Commissioner may
16 employ, without regard to chapter 31 of title 5,
17 United States Code, such officers and employees as
18 are necessary to administer the activities to be car-
19 ried out through the Competitive Medicare Agency.

20 “(2) FLEXIBILITY WITH RESPECT TO CIVIL
21 SERVICE LAWS.—

22 “(A) IN GENERAL.—The staff of the Com-
23 petitive Medicare Agency shall be appointed
24 without regard to the provisions of title 5,
25 United States Code, governing appointments in
26 the competitive service, and, subject to subpara-

graph (B), shall be paid without regard to the provisions of chapters 51 and 53 of such title (relating to classification and schedule pay rates).

“(B) MAXIMUM RATE.—In no case may the rate of compensation determined under subparagraph (A) exceed the rate of basic pay payable for level IV of the Executive Schedule under section 5315 of title 5, United States Code.

“(b) BUDGETARY MATTERS.—

“(1) SUBMISSION OF ANNUAL BUDGET.—The Commissioner shall prepare an annual budget for the Agency, which shall be submitted by the President to Congress without revision, together with the President’s annual budget for the Agency.

“(2) APPROPRIATIONS REQUESTS.—

“(A) STAFFING AND PERSONNEL.—Appropriations requests for staffing and personnel of the Agency shall be based upon a comprehensive work force plan, which shall be established and revised from time to time by the Commissioner.

“(B) ADMINISTRATIVE EXPENSES.—Appropriations for administrative expenses of the

1 Agency are authorized to be provided on a bien-
2 nial basis.

3 “(c) SEAL OF OFFICE.—

4 “(1) IN GENERAL.—The Commissioner shall
5 cause a seal of office to be made for the Agency of
6 such design as the Commissioner shall approve.

7 “(2) JUDICIAL NOTICE.—Judicial notice shall
8 be taken of the seal made under paragraph (1).

9 “(d) DATA EXCHANGES.—

10 “(1) DISCLOSURE OF RECORDS AND OTHER IN-
11 FORMATION.—Notwithstanding any other provision
12 of law (including subsection (b), (o), (p), (q), (r),
13 and (u) of section 552a of title 5, United States
14 Code)—

15 “(A) the Secretary shall disclose to the
16 Commissioner any record or information re-
17 quested in writing by the Commissioner for the
18 purpose of administering any program adminis-
19 tered by the Commissioner, if records or infor-
20 mation of such type were disclosed to the Ad-
21 ministrators of the Health Care Financing Ad-
22 ministration in the Department of Health and
23 Human Services under applicable rules, regula-
24 tions, and procedures in effect before the date

1 of enactment of the Medicare Prescription Drug
2 and Modernization Act of 2000; and

3 “(B) the Commissioner shall disclose to
4 the Secretary or to any State any record or in-
5 formation requested in writing by the Secretary
6 to be so disclosed for the purpose of admin-
7 istering any program administered by the Sec-
8 retary, if records or information of such type
9 were so disclosed under applicable rules, regula-
10 tions, and procedures in effect before the date
11 of enactment of the Medicare Prescription Drug
12 and Modernization Act of 2000.

13 “(2) EXCHANGE OF OTHER DATA.—The Com-
14 missioner and the Secretary shall periodically review
15 the need for exchanges of information not referred
16 to in paragraph (1) and shall enter into such agree-
17 ments as may be necessary and appropriate to pro-
18 vide information to each other or to States in order
19 to meet the programmatic needs of the requesting
20 agencies.

21 “(3) ROUTINE USE.—

22 “(A) IN GENERAL.—Any disclosure from a
23 system of records (as defined in section
24 552a(a)(5) of title 5, United States Code) pur-
25 suant to this subsection shall be made as a rou-

1 tine use under subsection (b)(3) of section 552a
2 of such title (unless otherwise authorized under
3 such section 552a).

“(B) COMPUTERIZED COMPARISON.—Any computerized comparison of records, including matching programs, between the Commissioner and the Secretary shall be conducted in accordance with subsections (o), (p), (q), (r), and (u) of section 552a of title 5, United States Code.

“(4) **TIMELY ACTION.**—The Commissioner and the Secretary shall each ensure that timely action is taken to establish any necessary routine uses for disclosures required under paragraph (1) or agreed to pursuant to paragraph (2).

15 “MEDICARE COMPETITION AND PRESCRIPTION DRUG
16 ADVISORY BOARD

17 “SEC. 2204. (a) ESTABLISHMENT OF BOARD.—
18 There is established a Medicare Competition and Prescrip-
19 tion Drug Advisory Board (in this section referred to as
20 the ‘Board’).

21 “(b) ADVICE ON POLICIES; REPORTS.—

“(1) ADVICE ON POLICIES.—On and after the date the Commissioner takes office, the Board shall advise the Commissioner on policies relating to the Medicare Competition and Prescription Drug Program under part B of this title and the

1 Medicare+Choice program under part C of title
2 XVIII.

3 “(2) REPORTS.—

4 “(A) IN GENERAL.—With respect to mat-
5 ters of the administration of part C of title
6 XVIII and part B of this title, the Board shall
7 submit to Congress and to the Commissioner of
8 the Competitive Medicare Agency such reports
9 as the Board determines appropriate. Each
10 such report may contain such recommendations
11 as the Board determines appropriate for legisla-
12 tive or administrative changes to improve the
13 administration of such parts. Each such report
14 shall be published in the Federal Register.

15 “(B) MAINTAINING INDEPENDENCE OF
16 BOARD.—The Board shall directly submit to
17 Congress reports required under subparagraph
18 (A). No officer or agency of the United States
19 may require the Board to submit to any officer
20 or agency of the United States for approval,
21 comments, or review, prior to the submission to
22 Congress of such reports.

23 “(c) STRUCTURE AND MEMBERSHIP OF THE
24 BOARD.—

1 “(1) MEMBERSHIP.—The Board shall be com-
2 posed of 7 members who shall be appointed as fol-
3 lows:

4 “(A) PRESIDENTIAL APPOINTMENTS.—

5 “(i) IN GENERAL.—3 members shall
6 be appointed by the President, by and with
7 the advice and consent of the Senate.

8 “(ii) LIMITATION.—Not more than 2
9 of such members shall be from the same
10 political party.

11 “(B) SENATORIAL APPOINTMENTS.—2
12 members (each member from a different polit-
13 ical party) shall be appointed by the President
14 pro tempore of the Senate with the advice of
15 the Chairman and the Ranking Minority Mem-
16 ber of the Committee on Finance of the Senate.

17 “(C) CONGRESSIONAL APPOINTMENTS.—2
18 members (each member from a different polit-
19 ical party) shall be appointed by the Speaker of
20 the House of Representatives, with the advice
21 of the Chairman and the Ranking Minority
22 Member of the Committee on Ways and Means
23 of the House of Representatives.

24 “(2) QUALIFICATIONS.—The members shall be
25 chosen on the basis of their integrity, impartiality,

and good judgment, and shall be individuals who are, by reason of their education, experience, and attainments, exceptionally qualified to perform the duties of members of the Board.

“(d) TERMS OF APPOINTMENT.—

“(1) IN GENERAL.—Subject to paragraph (2) each member of the Board shall serve for a term of 6 years.

“(2) CONTINUANCE IN OFFICE AND STAGGERED TERMS.—

“(A) CONTINUANCE IN OFFICE.—A member appointed to a term of office after the commencement of such term may serve under such appointment only for the remainder of such term.

“(B) STAGGERED TERMS.—The terms of service of the members initially appointed under this section shall begin on January 1, 2002, and expire as follows:

“(i) PRESIDENTIAL APPOINTMENTS.—

The terms of service of the members initially appointed by the President shall expire as designated by the President at the time of nomination, 1 each at the end of—

“(I) 2 years;

1 “(II) 4 years; and

2 “(III) 6 years.

3 “(ii) SENATORIAL APPOINTMENTS.—

4 The terms of service of members initially
5 appointed by the President pro tempore of
6 the Senate shall expire as designated by
7 the President pro tempore of the Senate at
8 the time of nomination, 1 each at the end
9 of.—

10 “(I) 3 years; and

11 “(II) 6 years.

12 “(iii) CONGRESSIONAL APPOINT-

13 MENTS.—The terms of service of members
14 initially appointed by the Speaker of the
15 House of Representatives shall expire as
16 designated by the Speaker of the House of
17 Representatives at the time of nomination,
18 1 each at the end of—

19 “(I) 4 years; and

20 “(II) 5 years.

21 “(C) REAPPOINTMENTS.—Any person ap-
22 pointed as a member of the Board may not
23 serve for more than 8 years.

24 “(D) VACANCIES.—Any member appointed
25 to fill a vacancy occurring before the expiration

1 of the term for which the member's predecessor
2 was appointed shall be appointed only for the
3 remainder of that term. A member may serve
4 after the expiration of that member's term until
5 a successor has taken office. A vacancy in the
6 Board shall be filled in the manner in which the
7 original appointment was made.

8 “(e) CHAIRPERSON.—A member of the Board shall
9 be designated by the President to serve as Chairperson
10 for a term of 4 years, coincident with the term of the
11 President, or until the designation of a successor.

12 “(f) EXPENSES AND PER DIEM.—Members of the
13 Board shall serve without compensation, except that, while
14 serving on business of the Board away from their homes
15 or regular places of business, members may be allowed
16 travel expenses, including per diem in lieu of subsistence,
17 as authorized by section 5703 of title 5, United States
18 Code, for persons in the Government employed intermit-
19 tently.

20 “(g) MEETING.—

21 “(1) IN GENERAL.—The Board shall meet at
22 the call of the Chairperson (in consultation with the
23 other members of the Board) not less than 4 times
24 each year to consider a specific agenda of issues, as

1 determined by the Chairperson in consultation with
2 the other members of the Board.

3 “(2) QUORUM.—Four members of the Board
4 (not more than 3 of whom may be of the same polit-
5 ical party) shall constitute a quorum for purposes of
6 conducting business.

7 “(h) FEDERAL ADVISORY COMMITTEE ACT.—The
8 Board shall be exempt from the provisions of the Federal
9 Advisory Committee Act (5 U.S.C. App.).

10 “(i) PERSONNEL.—

11 “(1) STAFF DIRECTOR.—The Board shall, with-
12 out regard to the provisions of title 5, United States
13 Code, relating to the competitive service, appoint a
14 Staff Director who shall be paid at a rate equivalent
15 to a rate established for the Senior Executive Serv-
16 ice under section 5382 of title 5, United States
17 Code.

18 “(2) STAFF.—

19 “(A) IN GENERAL.—The Board may em-
20 ploy, without regard to chapter 31 of title 5,
21 United States Code, such officers and employ-
22 ees as are necessary to administer the activities
23 to be carried out by the Board.

24 “(B) FLEXIBILITY WITH RESPECT TO
25 CIVIL SERVICE LAWS.—

1 “(i) IN GENERAL.—The staff of the
2 Board shall be appointed without regard to
3 the provisions of title 5, United States
4 Code, governing appointments in the com-
5 petitive service, and, subject to clause (ii),
6 shall be paid without regard to the provi-
7 sions of chapters 51 and 53 of such title
8 (relating to classification and schedule pay
9 rates).

10 “(ii) MAXIMUM RATE.—In no case
11 may the rate of compensation determined
12 under clause (i) exceed the rate of basic
13 pay payable for level IV of the Executive
14 Schedule under section 5315 of title 5,
15 United States Code.

16 “(j) AUTHORIZATION OF APPROPRIATIONS.—There
17 are authorized to be appropriated, out of the Federal Hos-
18 pital Insurance Trust Fund and the Federal Supplemental
19 Medical Insurance Trust Fund, and the general fund of
20 the Treasury, such sums as are necessary to carry out the
21 purposes of this section.”.

22 (b) EFFECTIVE DATE.—

23 (1) IN GENERAL.—The amendment made by
24 subsection (a) shall take effect on the date of enact-
25 ment of this Act.

1 (2) TIMING OF INITIAL APPOINTMENTS.—The
 2 Commissioner and Deputy Commissioner of the
 3 Competitive Medicare Agency may not be appointed
 4 before March 1, 2001.

5 (3) DUTIES WITH RESPECT TO ELIGIBILITY DE-
 6 TERMINATIONS AND ENROLLMENT.—The Commis-
 7 sioner of the Competitive Medicare Agency shall
 8 carry out enrollment under title XVIII of the Social
 9 Security Act, make eligibility determinations under
 10 such title, and carry out part C of such title for
 11 years beginning on or after January 1, 2003.

12 **SEC. 102. COMMISSIONER AS MEMBER OF THE BOARD OF**
 13 **TRUSTEES OF THE MEDICARE TRUST FUNDS.**

14 (a) IN GENERAL.—Sections 1817(b) and 1841(b) of
 15 the Social Security Act (42 U.S.C. 1395i(b); 1395t(b)) are
 16 each amended by striking “and the Secretary of Health
 17 and Human Services, all ex officio,” and inserting “, the
 18 Secretary of Health and Human Services, and the Com-
 19 missioner of the Competitive Medicare Agency, all ex offi-
 20 cio,”.

21 (b) EFFECTIVE DATE.—The amendments made by
 22 this subsection shall take effect on March 1, 2001.

1 **SEC. 103. SALARY INCREASE FOR THE HCFA ADMINIS-**
 2 **TRATOR.**

3 (a) IN GENERAL.—Section 5314 of title 5, United
 4 States Code, is amended by adding at the end the fol-
 5 lowing:

6 “Administrator of the Health Care Financing
 7 Administration.”.

8 (b) CONFORMING AMENDMENT.—Section 5315 of
 9 such title is amended by striking “Administrator of the
 10 Health Care Financing Administration.”.

11 (c) EFFECTIVE DATE.—The amendments made by
 12 this subsection take effect on March 1, 2001.

13 **Subtitle B—Redefined Medicare**
 14 **Solvency Measures**

15 **SEC. 151. REQUIREMENTS FOR ANNUAL FINANCIAL RE-**
 16 **PORTING AND OVERSIGHT OF MEDICARE**
 17 **PROGRAM.**

18 (a) IN GENERAL.—Section 1817 of the Social Secu-
 19 rity Act (42 U.S.C. 1395i) is amended by adding at the
 20 end the following new subsection:

21 “(1) COMBINED REPORT ON OPERATION AND STATUS
 22 OF THE TRUST FUND AND THE FEDERAL SUPPLE-
 23 MENTARY MEDICAL INSURANCE TRUST FUND.—

24 “(1) IN GENERAL.—In addition to the duty of
 25 the Board of Trustees to report to Congress under
 26 subsection (b), on the date the Board submits the

1 report required under subsection (b)(2), the Board
2 shall submit to Congress a report on the operation
3 and status of the Trust Fund and the Federal Sup-
4 plementary Medical Insurance Trust Fund estab-
5 lished under section 1841, including the Medicare
6 Prescription Drug Account within such Trust Fund
7 (in this subsection referred to as the ‘Trust Funds’).
8 Such report shall include the following information:

9 “(A) OVERALL SPENDING FROM THE GEN-
10 ERAL FUND OF THE TREASURY.—A statement
11 of total amounts obligated during the preceding
12 fiscal year from the General Revenues of the
13 Treasury to the Trust Funds for payment for
14 benefits covered under this title and part B of
15 title XXII, stated in terms of the total amount
16 and in terms of the percentage such amount
17 bears to all other amounts obligated from such
18 General Revenues during such fiscal year.

19 “(B) HISTORICAL OVERVIEW OF SPEND-
20 ING.—From the date of the inception of the
21 program of insurance under this title through
22 the fiscal year involved, a statement of the total
23 amounts referred to in subparagraph (A).

24 “(C) 10-YEAR AND 50-YEAR PROJEC-
25 TIONS.—An estimate of total amounts referred

1 to in subparagraph (A) required to be obligated
2 for payment for benefits covered under this title
3 for each of the 10 fiscal years succeeding the
4 fiscal year involved and for the 50-year period
5 beginning with the succeeding fiscal year.

6 “(D) RELATION TO GDP GROWTH.—A
7 comparison of the rate of growth of the total
8 amounts referred to in subparagraph (A) to the
9 rate of growth in the gross domestic product for
10 the same period.

11 “(2) PUBLICATION.—Each report submitted
12 under paragraph (1) shall be published by the Com-
13 mittee on Ways and Means as a public document.”.

14 (b) EFFECTIVE DATE.—The amendment made by
15 subsection (a) shall apply with respect to fiscal years be-
16 ginning on or after the date of enactment of this Act.

17 (c) CONGRESSIONAL HEARINGS.—It is the sense of
18 Congress that the committees of jurisdiction shall hold
19 hearings on the reports submitted under section 1817(l)
20 (42 U.S.C. 1395i(l)) of the Social Security Act.

1 **TITLE II—MEDICARE PRESCRIP-**
2 **TION DRUG AND SUPPLE-**
3 **MENTAL BENEFIT PROGRAM**

4 **SEC. 201. ESTABLISHMENT OF PROGRAM.**

5 (a) IN GENERAL.—Title XXII of the Social Security
6 Act, as added by section 101, is amended by adding at
7 the end the following new part:

8 “PART B—MEDICARE PRESCRIPTION DRUG AND
9 SUPPLEMENTAL BENEFIT PROGRAM

10 “ESTABLISHMENT OF PRESCRIPTION DRUG AND
11 SUPPLEMENTAL BENEFIT PROGRAM

12 “SEC. 2221. (a) PROVISION OF BENEFIT.—The
13 Commissioner shall establish a Prescription Drug and
14 Supplemental Benefit Program under which an eligible
15 beneficiary may voluntarily enroll and receive access to
16 covered outpatient prescription drugs and other benefits
17 through enrollment in a Medicare Prescription Plus plan
18 offered by a private entity or a Medicare+Choice plan of-
19 fered by a Medicare+Choice organization.

20 “(b) PROGRAM TO BEGIN IN 2003.—The Commis-
21 sioner shall establish the program under this part in a
22 manner so that benefits are first provided for months be-
23 ginning with January 2003.

1 “(c) VOLUNTARY NATURE OF PROGRAM.—Nothing
2 in this part shall be construed as requiring an eligible ben-
3 eficiary to enroll in the program under this part.

4 “(d) FINANCING.—The costs of providing benefits
5 under this part shall be payable from the Medicare Pre-
6 scription Drug Account.

7 “(e) NO EFFECT ON TITLE XVIII BENEFITS.—The
8 program under this part shall have no effect on the entitle-
9 ment to benefits under title XVIII.

10 “ENROLLMENT UNDER PROGRAM

11 “SEC. 2222. (a) ESTABLISHMENT OF PROCESS.—

12 “(1) IN GENERAL.—The Commissioner shall es-
13 tablish a process through which an eligible bene-
14 ficiary (including an eligible beneficiary enrolled in a
15 Medicare+Choice plan offered by a
16 Medicare+Choice organization) may make an elec-
17 tion to enroll under the program under this part.
18 Except as otherwise provided in this section, such
19 process shall be similar to the process for enrollment
20 in part B under section 1837.

21 “(2) REQUIREMENT OF ENROLLMENT.—An eli-
22 gible beneficiary must enroll under this part in order
23 to be eligible to receive benefits under this part.

24 “(b) ENROLLMENT PERIOD.—

25 “(1) IN GENERAL.—Except as provided in para-
26 graph (2) or (3), an eligible beneficiary may not en-

1 roll in the program under this part during any pe-
 2 riod after the beneficiary's initial enrollment period.

3 “(2) OPEN ENROLLMENT PERIOD FOR BENE-
 4 FICIARIES CURRENTLY COVERED.—In the case of an
 5 individual who is entitled to part A of title XVIII
 6 and enrolled under part B of such title as of Novem-
 7 ber 1, 2002, there shall be an open enrollment pe-
 8 riod of 6 months beginning on that date.

9 “(3) SPECIAL ENROLLMENT PERIOD FOR BENE-
 10 FICIARIES THAT LOSE OTHER DRUG COVERAGE.—

11 “(A) IN GENERAL.—Subject to subpara-
 12 graph (D), in the case of an applicable eligible
 13 beneficiary, the Commissioner shall establish
 14 procedures for permitting such beneficiary to
 15 enroll under the program under this part.

16 “(B) APPLICABLE ELIGIBLE BENE-
 17 FICIARY.—For purposes of this paragraph, the
 18 term ‘applicable eligible beneficiary’ means an
 19 eligible beneficiary who—

20 “(i) had applicable drug coverage; and

21 “(ii) involuntarily lost such coverage.

22 “(C) APPLICABLE DRUG COVERAGE DE-
 23 FINED.—For purposes of subparagraph (B),
 24 the term ‘applicable drug coverage’ means any
 25 of the following prescription drug coverage:

1 “(i) MEDICAID PRESCRIPTION DRUG
2 COVERAGE.—Prescription drug coverage
3 under a medicaid plan under title XIX, in-
4 cluding through the Program of All-inclu-
5 sive Care for the Elderly (PACE) under
6 section 1934, through a social health main-
7 tenance organization (referred to in section
8 4104(c) of the Balanced Budget Act of
9 1997), or through a Medicare+Choice
10 project that demonstrates the application
11 of capitation payment rates for frail elderly
12 medicare beneficiaries through the use of a
13 interdisciplinary team and through the
14 provision of primary care services to such
15 beneficiaries by means of such a team at
16 the nursing facility involved.

17 “(ii) PRESCRIPTION DRUG COVERAGE
18 UNDER GROUP HEALTH PLAN.—Any out-
19 patient prescription drug coverage under a
20 group health plan, including a health bene-
21 fits plan under the Federal Employees
22 Health Benefit Plan under chapter 89 of
23 title 5, United States Code, and a qualified
24 retiree prescription drug plan (as defined
25 in section 2232(e)(1)).

1 “(iii) PRESCRIPTION DRUG COVERAGE
2 UNDER CERTAIN MEDIGAP POLICIES.—
3 Coverage under a medicare supplemental
4 policy under section 1882 that provides
5 benefits for prescription drugs (whether or
6 not such coverage conforms to the stand-
7 ards for packages of benefits under section
8 1882(p)(1)), but only if the policy was in
9 effect on January 1, 2003.

10 “(iv) STATE PHARMACEUTICAL AS-
11 SISTANCE PROGRAM.—Coverage of pre-
12 scription drugs under a State pharma-
13 ceutical assistance program.

14 “(v) VETERANS’ COVERAGE OF PRE-
15 SCRIPTION DRUGS.—Coverage of prescrip-
16 tion drugs for veterans under chapter 17
17 of title 38, United States Code.

18 “(D) REQUIREMENTS.—The procedures
19 established under subparagraph (A) shall re-
20 quire that an applicable eligible beneficiary—

21 “(i) seek to enroll under the program
22 not later than 63 days after the date that
23 the beneficiary lost applicable drug cov-
24 erage; and

1 “(ii) submit evidence of the date that
2 the beneficiary lost such coverage along
3 with the application for enrollment in the
4 program under this part.

5 “(4) STUDY AND REPORT ON PERMITTING PART
6 B ONLY INDIVIDUALS TO ENROLL IN PROGRAM.—

7 “(A) STUDY.—The Commissioner shall
8 conduct a study on the need for rules relating
9 to permitting individuals who are enrolled under
10 part B of title XVIII but are not entitled to
11 benefits under part A to buy into the program
12 under this part.

13 “(B) REPORT.—Not later than January 1,
14 2002, the Commissioner shall submit a report
15 to Congress on the study conducted under sub-
16 paragraph (A), together with any recommenda-
17 tions for legislation that the Commissioner de-
18 termines to be appropriate as a result of such
19 study.

20 “(c) PERIOD OF COVERAGE.—

21 “(1) IN GENERAL.—Except as provided in para-
22 graph (2) and subject to paragraph (3), an eligible
23 beneficiary’s coverage under the program under this
24 part shall be effective for the period provided in sec-

1 tion 1838, as if that section applied to the program
2 under this part.

3 “(2) ENROLLMENT DURING OPEN AND SPECIAL
4 ENROLLMENT.—Subject to paragraph (3), an eligi-
5 ble beneficiary who enrolls under the program under
6 this part pursuant to paragraph (2) or (3) of sub-
7 section (b) shall be entitled to the benefits under
8 this part beginning on the first day of the month fol-
9 lowing the month in which such enrollment occurs.

10 “(3) LIMITATION.—Coverage under this part
11 shall not begin prior to January 1, 2003.

12 “(d) PROGRAM COVERAGE TERMINATED BY TERMI-
13 NATION OF COVERAGE UNDER PARTS A AND B OF TITLE
14 XVIII.—

15 “(1) IN GENERAL.—In addition to the causes of
16 termination specified in section 1838, the Commis-
17 sioner shall terminate an individual’s coverage under
18 the program under this part if the individual is no
19 longer enrolled in both parts A and B of title XVIII.

20 “(2) EFFECTIVE DATE.—The termination de-
21 scribed in paragraph (1) shall be effective on the ef-
22 fective date of termination of coverage under part A
23 of title XVIII or (if earlier) under part B of such
24 title.

1 “(e) FIRST ENROLLMENT PERIOD.—The Commis-
 2 sioner shall ensure that eligible beneficiaries are permitted
 3 to enroll under this part prior to January 1, 2003, in
 4 order to ensure that coverage under this part is effective
 5 as of such date.

6 “ELECTION OF A MEDICARE PRESCRIPTION PLUS PLAN

7 “SEC. 2223. (a) IN GENERAL.—

8 “(1) PROCESS.—

9 “(A) IN GENERAL.—Subject to paragraph
 10 (2), the Commissioner shall establish a process
 11 through which an eligible beneficiary who is en-
 12 rolled under this part shall make an annual
 13 election to enroll in a Medicare Prescription
 14 Plus plan offered by an eligible entity that
 15 serves the geographic area in which the bene-
 16 ficiary resides.

17 “(B) RULES.—In establishing the process
 18 under subparagraph (A), the Commissioner
 19 shall use rules that are consistent with the rules
 20 for enrollment and disenrollment with a
 21 Medicare+Choice plan under section 1851,
 22 including—

23 “(i) annual, coordinated election peri-
 24 ods, which shall be coordinated with such
 25 periods under part C of title XVIII;

1 “(ii) special election periods under
2 subsection (e)(4) of section 1851; and

3 “(iii) the guaranteed issue require-
4 ments under subsection (g) of such section.

5 “(2) MEDICARE+CHOICE ENROLLEES.—An eli-
6 gible beneficiary who is enrolled under this part and
7 enrolled in a Medicare+Choice plan offered by a
8 Medicare+Choice organization shall receive coverage
9 of benefits under this part through such plan if such
10 plan provides qualified prescription drug coverage. If
11 the Medicare+Choice plan in which the beneficiary
12 is enrolled does not provide such coverage, the bene-
13 ficiary shall receive such coverage through the elec-
14 tion of a Medicare Prescription Plus plan offered by
15 an eligible entity under this part.

16 “(b) ASSURING ACCESS TO PRESCRIPTION DRUG
17 COVERAGE IN AREAS WITH NO MEDICARE PRESCRIPTION
18 PLUS PLAN OR MEDICARE+CHOICE PLAN PROVIDING
19 DRUG COVERAGE AVAILABLE.—The Commissioner shall
20 develop procedures for the provision of the benefits re-
21 quired under section 2225(a) to each eligible beneficiary
22 that resides in an area where there are no Medicare Pre-
23 scription Plus plans or Medicare+Choice plans available
24 that provide qualified prescription drug coverage.

1 “BENEFICIARY INFORMATION

2 “SEC. 2224. (a) IN GENERAL.—The Commissioner
3 shall conduct activities that are designed to broadly dis-
4 seminate information to eligible beneficiaries (and pro-
5 spective eligible beneficiaries) regarding the coverage pro-
6 vided under this part.

7 “(b) REQUIREMENTS.—The activities conducted
8 under this subsection shall be—

9 “(1) similar to the activities performed by the
10 Commissioner under section 1851(d), including the
11 dissemination of comparative information; and

12 “(2) coordinated with the activities performed
13 by the Commissioner under such section and under
14 section 1804.

15 “OUTPATIENT PRESCRIPTION DRUG AND OTHER

16 SUPPLEMENTAL BENEFITS

17 “SEC. 2225. (a) REQUIREMENTS.—

18 “(1) IN GENERAL.—For purposes of this part
19 and part C of title XVIII, the term ‘qualified pre-
20 scription drug coverage’ means either of the fol-
21 lowing:

22 “(A) STANDARD COVERAGE WITH ACCESS
23 TO NEGOTIATED PRICES.—Standard coverage
24 (as defined in subsection (d)) and access to ne-
25 gotiated prices under subsection (f).

1 “(B) ACTUARIALLY EQUIVALENT COV-
2 ERAGE WITH ACCESS TO NEGOTIATED
3 PRICES.—Coverage of covered outpatient drugs
4 which meets the alternative coverage require-
5 ments of subsection (e) and access to negotiated
6 prices under subsection (f).

7 “(2) PERMITTING ADDITIONAL OUTPATIENT
8 PRESCRIPTION DRUG COVERAGE.—

9 “(A) IN GENERAL.—Subject to subpara-
10 graph (B) and section 2229(c)(2), nothing in
11 this part shall be construed as preventing quali-
12 fied prescription drug coverage from including
13 coverage of covered outpatient drugs that ex-
14 ceeds the coverage required under paragraph
15 (1).

16 “(B) REQUIREMENT.—An eligible entity
17 may not offer a Medicare Prescription Plus
18 plan that provides additional benefits pursuant
19 to subparagraph (A) in an area unless the eligi-
20 ble entity offering such plan also offers a Medi-
21 care Prescription Plus plan in the area that
22 only provides the coverage of prescription drugs
23 that is required under subsection (a)(1).

24 “(3) COST CONTROL MECHANISMS.—In pro-
25 viding qualified prescription drug coverage, the enti-

ty offering the Medicare Prescription Plus plan or the Medicare+Choice plan may use cost control mechanisms that are customarily used in employer-sponsored health care plans that offer coverage for outpatient prescription drugs, including the use of formularies, tiered copayments, selective contracting with providers of outpatient prescription drugs, and mail order pharmacies.

“(b) PERMITTING BENEFITS IN ADDITION TO OUTPATIENT PRESCRIPTION DRUG COVERAGE.—

“(1) IN GENERAL.—Subject to paragraph (2) and section 2229(c)(2), nothing in this part shall be construed as preventing a Medicare Prescription Plus plan from including coverage of benefits that are in addition to the benefits available under title XVIII, including coverage of beneficiary cost-sharing for benefits under such title.

“(2) REQUIREMENTS.—An eligible entity may not offer a Medicare Prescription Plus plan that provides additional benefits pursuant to paragraph (1) in an area unless—

“(A) the eligible entity offering such plan also offers a Medicare Prescription Plus plan in the area that only provides the coverage of pre-

1 scription drugs that is required under sub-
2 section (a)(1); and

3 “(B) if the additional benefits include any
4 of the core group of basic benefits described in
5 section 1882(p)(2)(B), the Medicare Prescrip-
6 tion Plus plan provides all of such core group
7 of basic benefits.

8 “(c) APPLICATION OF SECONDARY PAYOR PROVI-
9 SIONS.—The provisions of section 1852(a)(4) shall apply
10 under this part in the same manner as they apply under
11 part C of title XVIII.

12 “(d) STANDARD COVERAGE.—For purposes of this
13 part and part C of title XVIII, the ‘standard coverage’
14 is coverage of covered outpatient drugs that meets the fol-
15 lowing requirements:

16 “(1) DEDUCTIBLE.—The coverage has an an-
17 nual deductible—

18 “(A) for 2003, that is equal to \$250; or
19 “(B) for a subsequent year, that is equal
20 to the amount specified under this paragraph
21 for the previous year increased by the percent-
22 age specified in paragraph (5) for the year in-
23 volved.

1 Any amount determined under subparagraph (B)
2 that is not a multiple of \$5 shall be rounded to the
3 nearest multiple of \$5.

4 “(2) LIMITS ON COST-SHARING.—The coverage
5 has cost-sharing (for costs above the annual deduct-
6 ible specified in paragraph (1) and up to the initial
7 coverage limit under paragraph (3)) that is equal to
8 50 percent or that is actuarially consistent (using
9 processes established under subsection (g)) with an
10 average expected payment of 50 percent of such
11 costs.

12 “(3) INITIAL COVERAGE LIMIT.—Subject to
13 paragraph (4), the coverage has an initial coverage
14 limit on the maximum costs that may be recognized
15 for payment purposes (above the annual deduct-
16 ible)—

17 “(A) for 2003, that is equal to \$2,100; or

18 “(B) for a subsequent year, that is equal
19 to the amount specified in this paragraph for
20 the previous year, increased by the annual per-
21 centage increase described in paragraph (5) for
22 the year involved.

23 Any amount determined under subparagraph (B)
24 that is not a multiple of \$25 shall be rounded to the
25 nearest multiple of \$25.

1 “(4) LIMITATION ON OUT-OF-POCKET EXPENDI-
2 TURES BY BENEFICIARY.—

3 “(A) IN GENERAL.—Notwithstanding para-
4 graph (3), the coverage provides benefits with-
5 out any cost-sharing after the individual has in-
6 curred costs (as described in subparagraph (C))
7 for covered outpatient drugs in a year equal to
8 the annual out-of-pocket limit specified in sub-
9 paragraph (B).

10 “(B) ANNUAL OUT-OF-POCKET LIMIT.—
11 For purposes of this part, the ‘annual out-of-
12 pocket limit’ specified in this subparagraph—

13 “(i) for 2003, is equal to \$6,000; or

14 “(ii) for a subsequent year, is equal to
15 the amount specified in the subparagraph
16 for the previous year, increased by the an-
17 nual percentage increase described in para-
18 graph (5) for the year involved.

19 Any amount determined under clause (ii) that
20 is not a multiple of \$100 shall be rounded to
21 the nearest multiple of \$100.

22 “(C) APPLICATION.—In applying subpara-
23 graph (A)—

24 “(i) incurred costs shall only include
25 costs incurred for the annual deductible

(described in paragraph (1)), cost-sharing (described in paragraph (2)), and amounts for which benefits are not provided because of the application of the initial coverage limit described in paragraph (3); but

“(ii) costs shall be treated as incurred without regard to whether the individual or another person, including a State program, has paid for such costs, but shall not be counted insofar as such costs are covered as benefits under a Medicare Prescription Plus plan, a Medicare+Choice plan, or other third-party coverage.

“(5) ANNUAL PERCENTAGE INCREASE.—For purposes of this part, the annual percentage increase specified in this paragraph for a year is equal to the annual percentage increase in average per capita aggregate expenditures for covered outpatient drugs in the United States for medicare beneficiaries, as determined by the Commissioner for the 12-month period ending in July of the previous year.

“(e) ALTERNATIVE COVERAGE REQUIREMENTS.—A Medicare Prescription Plus plan or Medicare+Choice plan may provide a different prescription drug benefit design

1 from the standard coverage described in subsection (d) so
2 long as the following requirements are met:

3 “(1) ASSURING AT LEAST ACTUARIALLY EQUIV-
4 ALENT COVERAGE.—

5 “(A) ASSURING EQUIVALENT VALUE OF
6 TOTAL COVERAGE.—The actuarial value of the
7 total coverage (as determined under subsection
8 (g)) is at least equal to the actuarial value (as
9 so determined) of standard coverage.

10 “(B) ASSURING EQUIVALENT UNSUB-
11 SIDIZED VALUE OF COVERAGE.—The unsub-
12 sidized value of the coverage is at least equal to
13 the unsubsidized value of standard coverage.
14 For purposes of this subparagraph, the unsub-
15 sidized value of coverage is the amount by
16 which the actuarial value of the coverage (as
17 determined under subsection (g)) exceeds the
18 actuarial value of the reinsurance subsidy pay-
19 ments under section 2232 with respect to such
20 coverage.

21 “(C) ASSURING STANDARD PAYMENT FOR
22 COSTS AT INITIAL COVERAGE LIMIT.—The cov-
23 erage is designed, based upon an actuarially
24 representative pattern of utilization (as deter-
25 mined under subsection (g)), to provide for the

1 payment, with respect to costs incurred that are
2 equal to the sum of the deductible under sub-
3 section (d)(1) and the initial coverage limit
4 under subsection (d)(3), of an amount equal to
5 at least such initial coverage limit multiplied by
6 the percentage specified in subsection (d)(2).

7 Benefits other than qualified prescription drug cov-
8 erage shall not be taken into account for purposes
9 of this paragraph.

10 “(2) LIMITATION ON OUT-OF-POCKET EXPENDI-
11 TURES BY BENEFICIARIES.—The coverage provides
12 the limitation on out-of-pocket expenditures by bene-
13 ficiaries described in subsection (d)(4).

14 “(f) ACCESS TO NEGOTIATED PRICES.—Under quali-
15 fied prescription drug coverage offered by an eligible entity
16 or a Medicare+Choice organization, the entity or organi-
17 zation shall provide beneficiaries with access to negotiated
18 prices (including applicable discounts) used for payment
19 for covered outpatient drugs, regardless of the fact that
20 no benefits may be payable under the coverage with re-
21 spect to such drugs because of the application of cost-shar-
22 ing or an initial coverage limit (described in subsection
23 (d)(3)). In providing such access, the eligible entity or
24 Medicare+Choice organization shall issue a card pursuant
25 to section 2226(b)(1).

1 “(g) ACTUARIAL VALUATION; DETERMINATION OF
2 ANNUAL PERCENTAGE INCREASES.—

3 “(1) PROCESSES.—For purposes of this section,
4 the Commissioner shall establish processes and
5 methods—

6 “(A) for determining the actuarial valu-
7 ation of prescription drug coverage, including—

8 “(i) an actuarial valuation of standard
9 coverage and of the reinsurance subsidy
10 payments under section 2232;

11 “(ii) the use of generally accepted ac-
12 tuarial principles and methodologies; and

13 “(iii) applying the same methodology
14 for determinations of alternative coverage
15 under subsection (e) as is used with re-
16 spect to determinations of standard cov-
17 erage under subsection (d); and

18 “(B) for determining annual percentage in-
19 creases described in subsection (d)(5).

20 “(2) USE OF OUTSIDE ACTUARIES.—Under the
21 processes under paragraph (1)(A), eligible entities
22 and Medicare+Choice organizations may use actu-
23 arial opinions certified by independent, qualified ac-
24 tuaries to establish actuarial values.

1 “BENEFICIARY PROTECTIONS

2 “SEC. 2226. (a) DISSEMINATION OF INFORMA-
3 TION.—

4 “(1) GENERAL INFORMATION.—An eligible enti-
5 ty offering a Medicare Prescription Plus plan shall
6 disclose, in a clear, accurate, and standardized form
7 to each enrollee at the time of enrollment and at
8 least annually thereafter, the information described
9 in section 1852(c)(1) relating to such plan. Such in-
10 formation includes the following:

11 “(A) Access to covered outpatient drugs.

12 “(B) How any formulary used by the enti-
13 ty functions.

14 “(C) Co-payments, coinsurance, and de-
15 ductible requirements.

16 “(D) Grievance and appeals procedures.

17 “(2) DISCLOSURE UPON REQUEST OF GENERAL
18 COVERAGE, UTILIZATION, AND GRIEVANCE INFORMA-
19 TION.—Upon request of an individual eligible to en-
20 roll in a Medicare Prescription Plus plan, the eligible
21 entity offering such plan shall provide the informa-
22 tion described in section 1852(c)(2) to such indi-
23 vidual.

24 “(3) RESPONSE TO BENEFICIARY QUESTIONS.—
25 An eligible entity offering a Medicare Prescription

1 Plus plan shall have a mechanism for providing spe-
2 cific information to enrollees upon request, including
3 information on specific changes in its formulary.

4 “(4) CLAIMS INFORMATION.—An eligible entity
5 offering a Medicare Prescription Plus plan must fur-
6 nish to enrolled individuals in a form easily under-
7 standable to such individuals an explanation of bene-
8 fits (in accordance with section 1806(a) or in a com-
9 parable manner) and a notice of the benefits in rela-
10 tion to initial coverage limit and annual out-of-pock-
11 et limit for the current year, whenever prescription
12 drug benefits are provided under this part (except
13 that such notice need not be provided more often
14 than monthly).

15 “(b) ACCESS TO COVERED OUTPATIENT DRUGS.—

16 “(1) ACCESS TO NEGOTIATED PRICES FOR PRE-
17SCRIPTION DRUGS.—An eligible entity offering a
18 Medicare Prescription Plus plan shall issue such a
19 card that may be used by an enrolled beneficiary to
20 assure access to negotiated prices under section
21 2225(f) for the purchase of prescription drugs for
22 which coverage is not otherwise provided under the
23 Medicare Prescription Plus plan.

24 “(2) REQUIREMENTS ON DEVELOPMENT AND
25 APPLICATION OF FORMULARIES.—Insofar as an eli-

1 gible entity offering a Medicare Prescription Plus
2 plan uses a formulary with respect to qualified pre-
3 scription drug coverage, the following requirements
4 must be met:

5 “(A) INCLUSION OF DRUGS IN ALL THERA-
6 PEUTIC CATEGORIES.—The formulary must in-
7 clude drugs within all therapeutic categories
8 and classes of covered outpatient drugs (al-
9 though not necessarily for all drugs within such
10 categories and classes).

11 “(B) APPEALS AND EXCEPTIONS TO AP-
12 PLICATION.—The eligible entity must have, as
13 part of the appeals process under subsection
14 (e)(2), a process for appeals for denials of cov-
15 erage based on such application of the for-
16 mulary.

17 “(c) COST AND UTILIZATION MANAGEMENT.—

18 “(1) IN GENERAL.—An eligible entity shall have
19 in place—

20 “(A) an effective cost and drug utilization
21 management program, including appropriate in-
22 centives to use generic drugs, when appropriate;

23 “(B) quality assurance measures to reduce
24 medical errors and adverse drug interactions,

1 which may include the measures described in
2 paragraph (2); and

3 “(C) a program to control fraud, abuse,
4 and waste.

5 “(2) MEASURES.—The measures described in
6 this paragraph are beneficiary education programs,
7 counseling, medication refill reminders, and special
8 packaging.

9 “(d) GRIEVANCE MECHANISM.—An eligible entity
10 shall provide meaningful procedures for hearing and re-
11 solving grievances between the eligible entity (including
12 any entity or individual through which the eligible entity
13 provides covered benefits) and enrollees in a Medicare Pre-
14 scription Plus plan offered by the eligible entity in accord-
15 ance with section 1852(f).

16 “(e) COVERAGE DETERMINATIONS, RECONSIDER-
17 ATIONS, AND APPEALS.—

18 “(1) IN GENERAL.—An eligible entity shall
19 meet the requirements of section 1852(g) with re-
20 spect to covered benefits under the Medicare Pre-
21 scription Plus plan it offers under this part in the
22 same manner as such requirements apply to a
23 Medicare+Choice organization with respect to bene-
24 fits it offers under a Medicare+Choice plan under
25 part C of title XVIII.

1 “(2) APPEALS OF FORMULARY DETERMINA-
 2 TIONS.—Consistent with the requirements of section
 3 1852(g), an eligible entity shall establish a process
 4 for appeals of formulary determinations.

5 “(f) CONFIDENTIALITY AND ACCURACY OF EN-
 6 ROLLEE RECORDS.—An eligible entity shall meet the re-
 7 quirements of section 1852(h) with respect to enrollees
 8 under this part in the same manner as such requirements
 9 apply to a Medicare+Choice organization with respect to
 10 enrollees under part C of title XVIII.

11 “(g) UNIFORM PREMIUM.—An eligible entity shall
 12 ensure that the premium for a Medicare Prescription Plus
 13 plan charged under this section is the same for all individ-
 14 uals enrolled in the plan in the same service area.

15 “REQUIREMENTS FOR ENTITIES OFFERING MEDICARE
 16 PRESCRIPTION PLUS PLANS

17 “SEC. 2227. (a) GENERAL REQUIREMENTS.—An eli-
 18 gible entity offering a Medicare Prescription Plus plan
 19 shall meet the following requirements:

20 “(1) LICENSURE.—Subject to subsection (c),
 21 the entity is organized and licensed under State law
 22 as a risk-bearing entity eligible to offer health insur-
 23 ance or health benefits coverage in each State in
 24 which it offers a Medicare Prescription Plus plan.

25 “(2) ASSUMPTION OF FULL FINANCIAL RISK.—

1 “(A) IN GENERAL.—Subject to subpara-
2 graph (B), the entity assumes full financial risk
3 on a prospective basis for the benefits that it
4 offers under a Medicare Prescription Plus plan
5 and that is not covered under reinsurance
6 under section 2232.

7 “(B) REINSURANCE PERMITTED.—The en-
8 tity may obtain insurance or make other ar-
9 rangements for the cost of coverage provided to
10 any enrolled member under this part.

11 “(3) SOLVENCY FOR UNLICENSED ENTITIES.—
12 In the case of an eligible entity that is not described
13 in paragraph (1), the entity shall meet solvency
14 standards established by the Commissioner under
15 subsection (d).

16 “(b) CONTRACT REQUIREMENTS.—The Commis-
17 sioner shall not permit an eligible beneficiary to elect a
18 Medicare Prescription Plus plan offered by an eligible en-
19 tity under this part, and the entity shall not be eligible
20 for payments under section 2230, 2231(e), or 2232, unless
21 the Commissioner has entered into a contract under this
22 subsection with the entity with respect to the offering of
23 such plan. Such a contract with an entity may cover more
24 than 1 Medicare Prescription Plus plan. Such contract
25 shall provide that the entity agrees to comply with the ap-

1 plicable requirements and standards of this part and the
2 terms and conditions of payment as provided for in this
3 part.

4 “(c) WAIVER OF CERTAIN REQUIREMENTS TO EX-
5 PAND CHOICE.—

6 “(1) IN GENERAL.—In the case of an eligible
7 entity that seeks to offer a Medicare Prescription
8 Plus plan in a State, the Commissioner shall waive
9 the requirement of subsection (a)(1) that the entity
10 be licensed in that State if the Commissioner deter-
11 mines, based on the application and other evidence
12 presented to the Commissioner, that any of the
13 grounds for approval of the application described in
14 paragraph (2) have been met.

15 “(2) GROUNDS FOR APPROVAL.—The grounds
16 for approval under this paragraph are the grounds
17 for approval described in subparagraphs (B), (C),
18 and (D) of section 1855(a)(2), and also include the
19 application by a State of any grounds other than
20 those required under Federal law.

21 “(3) APPLICATION OF MEDICARE+CHOICE PSO
22 WAIVER PROCEDURES.—With respect to an applica-
23 tion for a waiver (or a waiver granted) under this
24 subsection, the provisions of subparagraphs (E), (F),
25 and (G) of section 1855(a)(2) shall apply.

1 “(4) LICENSURE DOES NOT SUBSTITUTE FOR
2 OR CONSTITUTE CERTIFICATION.—The fact that an
3 entity is licensed in accordance with subsection
4 (a)(1) does not deem the eligible entity to meet other
5 requirements imposed under this part for an eligible
6 entity.

7 “(5) REFERENCES TO CERTAIN PROVISIONS.—
8 For purposes of this subsection, in applying the pro-
9 visions of section 1855(a)(2) under this subsection
10 to Medicare Prescription Plus plans and eligible
11 entities—

12 “(A) any reference to a waiver application
13 under section 1855 shall be treated as a ref-
14 erence to a waiver application under paragraph
15 (1); and

16 “(B) any reference to solvency standards
17 were treated as a reference to solvency stand-
18 ards established under subsection (d).

19 “(d) SOLVENCY STANDARDS FOR NON-LICENSED
20 ENTITIES.—

21 “(1) ESTABLISHMENT.—The Commissioner
22 shall establish, by not later than October 1, 2001,
23 financial solvency and capital adequacy standards
24 that an entity that does not meet the requirements

of subsection (a)(1) must meet to qualify as an eligible entity under this part.

“(2) COMPLIANCE WITH STANDARDS.—An eligible entity that is not licensed by a State under subsection (a)(1) and for which a waiver application has been approved under subsection (c) shall meet solvency and capital adequacy standards established under paragraph (1). The Commissioner shall establish certification procedures for such eligible entities with respect to such solvency standards in the manner described in section 1855(c)(2).

“(e) OTHER STANDARDS.—The Commissioner shall establish by regulation other standards (not described in subsection (d)) for eligible entities and Medicare Prescription Plus plans consistent with, and to carry out, this part. The Commissioner shall publish such regulations by October 1, 2001.

“(f) RELATION TO STATE LAWS.—

“(1) IN GENERAL.—The standards established under this section shall supersede any State law or regulation (including standards described in paragraph (2)) with respect to Medicare Prescription Plus plans which are offered by eligible entities under this part to the extent such law or regulation is inconsistent with such standards, in the same

1 manner as such laws and regulations are superseded
2 under section 1856(b)(3).

3 “(2) STANDARDS SPECIFICALLY SUPER-
4 SEDED.—State standards relating to the following
5 are superseded under this section:

6 “(A) Benefit requirements.

7 “(B) Requirements relating to inclusion or
8 treatment of providers.

9 “(C) Coverage determinations (including
10 related appeals and grievance processes).

11 “(3) PROHIBITION OF STATE IMPOSITION OF
12 PREMIUM TAXES.—No State may impose a premium
13 tax or similar tax with respect to premiums paid to
14 eligible entities for Medicare Prescription Plus plans
15 under this part, or with respect to any payments
16 made to such an entity by the Commissioner under
17 this part.

18 “SUBMISSION OF MEDICARE PRESCRIPTION PLUS PLANS

19 “SEC. 2228. (a) IN GENERAL.—Each eligible entity
20 that intends to offer a Medicare Prescription Plus plan
21 in a year (beginning with 2003) shall submit to the Com-
22 missioner, at such time and in such manner as the Com-
23 missioner may specify, such information as the Commis-
24 sioner may require, including the information described in
25 subsection (b).

1 “(b) INFORMATION DESCRIBED.—The information
2 described in this subsection includes information on each
3 of the following:

4 “(1) A description of the benefits under the
5 plan, including any supplemental benefits pursuant
6 to section 2225(b).

7 “(2) Information on the actuarial value of the
8 qualified prescription drug coverage.

9 “(3) Information on the monthly premium to be
10 charged for all benefits, including an actuarial cer-
11 tification of—

12 “(A) the actuarial basis for such premium;

13 “(B) the portion of such premium attrib-
14 utable to benefits in excess of standard cov-
15 erage; and

16 “(C) the reduction in such premium result-
17 ing from the reinsurance subsidy payments pro-
18 vided under section 2232.

19 “(4) The service area for the plan.

20 “(5) Such other information as the Commis-
21 sioner may require to carry out this part.

22 “APPROVAL OF MEDICARE PRESCRIPTION PLUS PLANS

23 “SEC. 2229. (a) IN GENERAL.—The Commissioner
24 shall review the information filed under section 2228 and
25 shall approve or disapprove the Medicare Prescription
26 Plus plan.

1 “(b) NEGOTIATION.—In exercising such authority,
 2 the Commissioner shall have the same authority to nego-
 3 tiate the terms and conditions of the premiums submitted
 4 and other terms and conditions of plans as the Director
 5 of the Office of Personnel Management has with respect
 6 to health benefits plans under chapter 89 of title 5, United
 7 States Code.

8 “(c) SPECIAL RULES FOR APPROVAL.—

9 “(1) SERVICE AREA.—The Commissioner may
 10 approve a service area submitted under section
 11 2228(b)(4) only if the Commissioner finds that—

12 “(A) the use of such an area is consistent
 13 with the purposes of this part; and

14 “(B) the service area for the plan is not
 15 designed so as to discriminate based on the
 16 health status, economic status, or prior receipt
 17 of health care of eligible beneficiaries.

18 “(2) AVOIDANCE OF FAVORABLE SELECTION.—
 19 The Commissioner may approve a Medicare Pre-
 20 scription Plus plan submitted under section 2228
 21 only if the benefits under such plan—

22 “(A) include the required benefits under
 23 section 2225(a)(1); and

“(B) are not designed in such a manner that the Commissioner finds is likely to result in favorable selection of eligible beneficiaries.

“PAYMENTS TO MEDICARE PRESCRIPTION PLUS PLANS
FOR BENEFITS

“SEC. 2230. (a) IN GENERAL.—Subject to subsection (b), for each year (beginning with 2003), the Commissioner shall pay to each eligible entity offering a Medicare Prescription Plus plan in which an eligible beneficiary is enrolled an amount equal to—

“(1) the full amount of the premium approved under section 2229 on behalf of each eligible beneficiary enrolled in such plan for the year; minus

“(2) the amount of any fees imposed on the entity pursuant to section 2233).

“(b) PAYMENT TERMS.—Payment under this section to an eligible entity offering a Medicare Prescription Plus plan shall be made in a manner determined by the Commissioner and based upon the manner in which payments are made under section 1853(a) (relating to payments to Medicare+Choice organizations).

“COMPUTATION AND COLLECTION OF BENEFICIARY
SHARE OF PREMIUM

“SEC. 2231. (a) COMPUTATION.—

“(1) AMOUNT.—The annual beneficiary premium for enrollment in a Medicare Prescription Plus

1 plan providing coverage under this part for a year
2 shall be an amount equal to—

3 “(A) an amount equal to the full amount
4 of the premium approved under section 2229
5 for the plan in which the beneficiary is enrolled;
6 minus

7 “(B) the amount of the discount deter-
8 mined under subsection (b).

9 “(2) COLLECTION OF PREMIUM AMOUNT IN
10 SAME MANNER AS PART B PREMIUM.—

11 “(A) IN GENERAL.—The amount of the
12 annual beneficiary premium determined under
13 paragraph (1) shall be collected and credited to
14 the Medicare Prescription Drug Account in the
15 same manner as the monthly premium deter-
16 mined under section 1839 is collected and cred-
17 ited to the Federal Supplementary Medical In-
18 surance Trust Fund under section 1840.

19 “(B) INFORMATION NECESSARY FOR COL-
20 LECTION.—In order to carry out subparagraph
21 (A), the Commissioner shall transmit to the
22 Commissioner of Social Security—

23 “(i) at the beginning of each year, the
24 name, social security account number, and
25 annual beneficiary premium owed by each

individual enrolled in a Medicare Prescription Plus plan for each month during the year; and

“(ii) periodically throughout the year, information to update the information previously transmitted under this paragraph for the year.

“(b) DISCOUNTS FOR REQUIRED DRUG PORTION OF PREMIUM.—

“(1) FULL PREMIUM DISCOUNT AND REDUCTION OF COST-SHARING FOR INDIVIDUALS WITH INCOME BELOW 135 PERCENT OF FEDERAL POVERTY LEVEL.—In the case of a low-income individual (as defined in paragraph (5)(A)) who is determined to have income that does not exceed 135 percent of the Federal poverty level, the individual is entitled under this section—

“(A) to a premium discount equal to 100 percent of the amount described in subsection (c); and

“(B) subject to subsection (d), to the substitution for the beneficiary cost-sharing described in paragraphs (1) and (2) of section 2225(d) (up to the initial coverage limit speci-

1 fied in paragraph (3) of such section) of
2 amounts that are nominal.

3 “(2) SLIDING SCALE PREMIUM DISCOUNT FOR
4 INDIVIDUALS WITH INCOME ABOVE 135, BUT BELOW
5 150 PERCENT, OF FEDERAL POVERTY LEVEL.—In
6 the case of a low-income individual who is deter-
7 mined to have income that exceeds 135 percent, but
8 does not exceed 150 percent, of the Federal poverty
9 level, the individual is entitled under this section to
10 a premium discount determined on a linear sliding
11 scale ranging from 100 percent of the amount de-
12 scribed in subsection (c) for individuals with incomes
13 at 135 percent of such level to 25 percent of such
14 amount for individuals with incomes at 150 percent
15 of such level.

16 “(3) PARTIAL PREMIUM DISCOUNT FOR INDIVIDUALS WITH INCOME ABOVE 150 PERCENT OF
17 FEDERAL POVERTY LEVEL.—In the case of an eligi-
18 ble beneficiary who is not a low-income individual,
19 the beneficiary is entitled under this section to a
20 premium discount equal to 25 percent of the amount
21 described in subsection (c).

22 “(4) TAX TREATMENT OF PREMIUM DIS-
23 COUNT.—
24

1 “(A) IN GENERAL.—For purposes of the
2 Internal Revenue Code of 1986, the premium
3 discount determined under this subsection for
4 an eligible beneficiary for a year shall be in-
5 cluded in the gross income of the beneficiary for
6 the year.

7 “(B) STATEMENT OF TAXABLE AMOUNT.—
8 Not later than January 31 of each year (begin-
9 ning with 2004), the Commissioner shall
10 provide—

11 “(i) each eligible beneficiary enrolled
12 under this part with a statement that de-
13 scribes the amount of the discount that is
14 required to be included in the gross income
15 of the beneficiary for the previous year
16 pursuant to subparagraph (A); and

17 “(ii) the Secretary of the Treasury
18 with the information described in clause
19 (i).

20 “(5) DETERMINATION OF ELIGIBILITY.—

21 “(A) LOW-INCOME INDIVIDUAL DE-
22 FINED.—For purposes of this section, subject
23 to subparagraph (D), the term ‘low-income indi-
24 vidual’ means an individual who—

1 “(i) is eligible to enroll, and has en-
2 rolled, under this part;

3 “(ii) has income below 150 percent of
4 the Federal poverty line; and

5 “(iii) meets the resources requirement
6 described in section 1905(p)(1)(C).

7 “(B) DETERMINATIONS.—The determina-
8 tion of whether an individual residing in a State
9 is a low-income individual and the amount of
10 such individual’s income shall be determined
11 under the State medicaid plan for the State
12 under section 1935(a). In the case of a State
13 that does not operate such a medicaid plan (ei-
14 ther under title XIX or under a statewide waiv-
15 er granted under section 1115), such deter-
16 mination shall be made under arrangements
17 made by the Commissioner.

18 “(C) INCOME DETERMINATIONS.—For pur-
19 poses of applying this section—

20 “(i) income shall be determined in the
21 manner described in section
22 1905(p)(1)(B); and

23 “(ii) the term ‘Federal poverty line’
24 means the official poverty line (as defined
25 by the Office of Management and Budget,

and revised annually in accordance with section 673(2) of the Omnibus Budget Reconciliation Act of 1981) applicable to a family of the size involved.

“(D) TREATMENT OF TERRITORIAL RESIDENTS.—In the case of an individual who is not a resident of the 50 States or the District of Columbia, the individual is not eligible to be a low-income individual but may be eligible for financial assistance with prescription drug expenses under section 1935(e).

“(e) PREMIUM DISCOUNT AMOUNT.—The premium discount amount described in this subsection for an eligible beneficiary residing in an area is an amount equal to—

“(1) in the case of an individual enrolled in a Medicare Prescription Plus plan, the actuarial value of the standard drug coverage provided under the plan (determined without regard to any premium discount under this section); and

“(2) in the case of an individual enrolled in a Medicare+Choice plan that provides qualified prescription drug coverage, the standard premium computed under section 1851(j)(5)(A)(iii).

“(d) RULES IN APPLYING COST-SHARING SUBSIDIES.—

1 “(1) IN GENERAL.—In applying subsection
2 (b)(1)(B)—

3 “(A) the maximum amount of subsidy that
4 may be provided with respect to an enrollee for
5 a year may not exceed 95 percent of the max-
6 imum cost-sharing described in such subsection
7 that may be incurred for standard coverage;

8 “(B) the Commissioner shall determine
9 what is ‘nominal’ taking into account the rules
10 applied under section 1916(a)(3); and

11 “(C) nothing in this part shall be con-
12 strued as preventing a plan or provider from
13 waiving or reducing the amount of cost-sharing
14 otherwise applicable.

15 “(2) LIMITATION ON CHARGES.—In the case of
16 a low-income individual receiving cost-sharing sub-
17 sidies under subsection (b)(1)(B), the eligible entity
18 may not charge more than a nominal amount in
19 cases in which the cost-sharing subsidy is provided
20 under such subsection.

21 “(e) ADMINISTRATION OF COST-SHARING PRO-
22 GRAM.—The Commissioner shall provide a process where-
23 by, in the case of a low-income individual who is eligible
24 for reduced cost-sharing under subsection (b)(1)(B) and
25 is enrolled in a Medicare Prescription Plus plan or a

1 Medicare+Choice plan under which qualified prescription
2 drug coverage is provided—

3 “(1) the Commissioner provides for a notifica-
4 tion of the eligible entity or Medicare+Choice orga-
5 nization involved that the individual is eligible for
6 such reduced cost-sharing;

7 “(2) the entity or organization involved reduces
8 the cost-sharing pursuant to this section and sub-
9 mits to the Commissioner information on the
10 amount of such reduction; and

11 “(3) the Commissioner periodically and on a
12 timely basis reimburses the entity or organization
13 for the amount of such reductions.

14 The reimbursement under paragraph (3) may be com-
15 puted on a capitated basis, taking into account the actu-
16 arial value of the reductions and with appropriate adjust-
17 ments to reflect differences in the risks actually involved.

18 “(f) RELATION TO MEDICAID PROGRAM.—

19 “(1) IN GENERAL.—For provisions providing
20 for eligibility determinations, and additional financ-
21 ing, under the medicaid program, see section 1935.

22 “(2) MEDICAID PROVIDING WRAP AROUND BEN-
23 EFITS.—The coverage provided under this part is
24 primary payor to benefits for prescribed drugs pro-
25 vided under the medicaid program under title XIX.

1 “ADDITIONAL PRESCRIPTION DRUG SUBSIDIES THROUGH
2 REINSURANCE

3 “SEC. 2232. (a) REINSURANCE SUBSIDY PAY-
4 MENT.—In order to reduce premium levels applicable to
5 qualified prescription drug coverage for all medicare bene-
6 ficiaries, to reduce adverse selection among Medicare Pre-
7 scription Plus plans and Medicare+Choice plans that pro-
8 vide qualified prescription drug coverage, and to promote
9 the participation of eligible entities under this part, the
10 Commissioner shall provide in accordance with this section
11 for payment to a qualifying entity (as defined in sub-
12 section (b)) of the reinsurance payment amount (as de-
13 fined in subsection (c)) for excess costs incurred in pro-
14 viding qualified prescription drug coverage—

15 “(1) for individuals enrolled with a Medicare
16 Prescription Plus plan under this part;

17 “(2) for individuals enrolled with a
18 Medicare+Choice plan that provides qualified pre-
19 scription drug coverage under part C of title XVIII;
20 and

21 “(3) for medicare secondary payer eligible indi-
22 viduals (described in subsection (e)(3)(D)) who are
23 enrolled in a qualified retiree prescription drug plan.

24 This section constitutes budget authority in advance of ap-
25 propriations Acts and represents the obligation of the

1 Commissioner to provide for the payment of amounts pro-
2 vided under this section.

3 “(b) QUALIFYING ENTITY DEFINED.—For purposes
4 of this section, the term ‘qualifying entity’ means any of
5 the following that has entered into an agreement with the
6 Commissioner to provide the Commissioner with such in-
7 formation as may be required to carry out this section:

8 “(1) An eligible entity offering a Medicare Pre-
9 scription Plus plan under this part.

10 “(2) A Medicare+Choice organization that pro-
11 vides qualified prescription drug coverage under a
12 Medicare+Choice plan under part C of title XVIII.

13 “(3) The sponsor of a qualified retiree prescrip-
14 tion drug plan (as defined in subsection (e)).

15 “(c) REINSURANCE PAYMENT AMOUNT.—

16 “(1) IN GENERAL.—Subject to subsection (e)(2)
17 and paragraph (4), the reinsurance payment amount
18 under this subsection for a qualified beneficiary (as
19 defined in subsection (f)(1)) for a coverage year (as
20 defined in subsection (f)(2)) is an amount equal to
21 80 percent of the allowable costs attributable to the
22 portion of the individual’s gross covered prescription
23 drug costs for the year that exceeds \$7,050.

24 “(2) ALLOWABLE COSTS.—For purposes of this
25 section, the term ‘allowable costs’ means, with re-

1 spect to gross covered prescription drug costs under
2 a plan described in subsection (b) offered by a quali-
3 fying entity, the part of such costs that are actually
4 paid under the plan, but in no case more than the
5 part of such costs that would have been paid under
6 the plan if the prescription drug coverage under the
7 plan were standard coverage.

8 “(3) GROSS COVERED PRESCRIPTION DRUG
9 COSTS.—For purposes of this section, the term
10 ‘gross covered prescription drug costs’ means, with
11 respect to an enrollee with a qualifying entity under
12 a plan described in subsection (b) during a coverage
13 year, the costs incurred under the plan for covered
14 prescription drugs dispensed during the year, includ-
15 ing costs relating to the deductible, whether paid by
16 the enrollee or under the plan, regardless of whether
17 the coverage under the plan exceeds standard cov-
18 erage and regardless of when the payment for such
19 drugs is made.

20 “(4) INDEXING DOLLAR AMOUNT.—

21 “(A) AMOUNT FOR 2003.—The dollar
22 amount applied under paragraph (1) for 2003
23 shall be the dollar amount specified in such
24 paragraph.

“(B) FOR 2004.—The dollar amount applied under paragraph (1) for 2004 shall be the dollar amount specified in such paragraph increased by the annual percentage increase described in section 2225(d)(5) for 2004.

“(C) FOR SUBSEQUENT YEARS.—The dollar amount applied under paragraph (1) for a year after 2004 shall be the dollar amount (under this paragraph) applied under paragraph (1) for the preceding year increased by the annual percentage increase described in section 2225(d)(5) for the year involved.

“(D) ROUNDING.—Any amount, determined under the preceding provisions of this paragraph for a year, which is not a multiple of \$5 shall be rounded to the nearest multiple of \$5.

“(d) PAYMENT METHODS.—

“(1) IN GENERAL.—Payments under this section shall be based on such a method as the Commissioner determines. The Commissioner may establish a payment method by which interim payments of amounts under this section are made during a year based on the Commissioner’s best estimate of

1 amounts that will be payable after obtaining all of
2 the information.

3 “(2) SOURCE OF PAYMENTS.—Payments under
4 this section shall be made from the Medicare Pre-
5 scription Drug Account.

6 “(e) QUALIFIED RETIREE PRESCRIPTION DRUG
7 PLAN DEFINED.—

8 “(1) IN GENERAL.—For purposes of this sec-
9 tion, the term ‘qualified retiree prescription drug
10 plan’ means employment-based retiree health cov-
11 erage (as defined in paragraph (3)(A)) if, with re-
12 spect to an individual enrolled (or eligible to be en-
13 rolled) under this part who is covered under the
14 plan, the following requirements are met:

15 “(A) ASSURANCE.—The sponsor of the
16 plan shall annually attest, and provide such as-
17 surances as the Commissioner may require, that
18 the coverage meets the requirements for quali-
19 fied prescription drug coverage.

20 “(B) AUDITS.—The sponsor (and the plan)
21 shall maintain, and afford the Commissioner
22 access to, such records as the Commissioner
23 may require for purposes of audits and other
24 oversight activities necessary to ensure the ade-
25 quacy of prescription drug coverage, the accu-

1 racy of payments made, and such other matters
2 as may be appropriate.

3 “(C) OTHER REQUIREMENTS.—The spon-
4 sor of the plan shall comply with such other re-
5 quirements as the Commissioner finds nec-
6 essary to administer the program under this
7 section.

8 “(2) LIMITATION ON BENEFIT ELIGIBILITY.—
9 No payment shall be provided under this section
10 with respect to an individual who is enrolled under
11 a qualified retiree prescription drug plan unless the
12 individual is a medicare secondary payer eligible in-
13 dividual who—

14 “(A) is covered under the plan; and

15 “(B) is eligible to obtain qualified prescrip-
16 tion drug coverage under this part but did not
17 elect such coverage (either through a Medicare
18 Prescription Plus plan or through a
19 Medicare+Choice plan).

20 “(3) DEFINITIONS.—As used in this section:

21 “(A) EMPLOYMENT-BASED RETIREE
22 HEALTH COVERAGE.—The term ‘employment-
23 based retiree health coverage’ means health in-
24 surance or other coverage of health care costs
25 for medicare secondary payer eligible individ-

1 uals (or for such individuals and their spouses
2 and dependents) based on their status as
3 former employees or labor union members.

4 “(B) EMPLOYER.—The term ‘employer’
5 has the meaning given such term by section
6 3(5) of the Employee Retirement Income Secu-
7 rity Act of 1974 (except that such term shall
8 include only employers of 2 or more employees).

9 “(C) SPONSOR.—The term ‘sponsor’
10 means a plan sponsor, as defined in section
11 3(16)(B) of the Employee Retirement Income
12 Security Act of 1974.

13 “(D) MEDICARE SECONDARY PAYER INDIVIDUAL.—The term ‘medicare secondary payer
14 eligible individual’ means, with respect to a
15 plan, an individual who is covered under the
16 plan and with respect to whom the plan is not
17 a primary plan (as defined in section
18 1862(b)(2)(A)).

19
20 “(f) GENERAL DEFINITIONS.—For purposes of this
21 section:

22 “(1) QUALIFIED BENEFICIARY.—The term
23 ‘qualified beneficiary’ means an individual who—

24 “(A) is enrolled with a Medicare Prescrip-
25 tion Plus plan under this part;

“(B) is enrolled with a Medicare+Choice plan that provides qualified prescription drug coverage under part C of title XVIII; or

“(C) is covered as a medicare secondary payer eligible individual under a qualified retiree prescription drug plan.

“(2) COVERAGE YEAR.—The term ‘coverage year’ means a calendar year in which covered outpatient drugs are dispensed if a claim for payment is made under the plan for such drugs, regardless of when the claim is paid.

“PLAN FEES FOR ADMINISTRATIVE COSTS

“SEC. 2233. (a) IN GENERAL.—The Commissioner may levy on Medicare Prescription Plus plans and Medicare+Choice plans that provide drug coverage pursuant to this part an assessment sufficient to pay the estimated expenses of the Commissioner for administering the program under this part.

“(b) DEPOSITS AND USE.—The assessments described in subsection (a) shall be—

“(1) deposited into the Medicare Prescription Drug Account; and

“(2) available for administering the program under this part without regard to amounts provided for in advance by appropriations Acts.

1 “MEDICARE PRESCRIPTION DRUG ACCOUNT

2 “SEC. 2234. (a) ESTABLISHMENT.—There is created
3 within the Federal Supplementary Medical Insurance
4 Trust Fund established under section 1841 an account to
5 be known as the ‘Medicare Prescription Drug Account’.

6 “(b) AMOUNTS IN ACCOUNT.—

7 “(1) IN GENERAL.—The Medicare Prescription
8 Drug Account shall consist of—

9 “(A) such amounts as may be deposited in,
10 or appropriated to, such account as provided in
11 this part; and

12 “(B) such gifts and bequests as may be
13 made as provided in section 201(i)(1).

14 “(2) SEPARATION OF FUNDS.—Funds provided
15 under this part to the Medicare Prescription Drug
16 Account shall be kept separate from all other funds
17 within the Federal Supplemental Medical Insurance
18 Trust Fund.

19 “(c) PAYMENTS FROM ACCOUNT.—

20 “(1) IN GENERAL.—The Managing Trustee
21 shall pay from time to time from the Medicare Pre-
22 scription Drug Account such amounts as the Com-
23 missioner certifies are necessary to make the pay-
24 ments provided for by this part, and the payments

1 with respect to administrative expenses in accord-
2 ance with section 201(g).

3 “(2) TRANSFERS TO MEDICAID ACCOUNT FOR
4 INCREASED ADMINISTRATIVE COSTS.—The Man-
5 aging Trustee shall transfer from time to time from
6 the Account to the Grants to States for Medicaid ac-
7 count amounts the Secretary certifies are attrib-
8 utable to increases in payment resulting from the
9 application of a higher Federal matching percentage
10 under section 1935(b).

11 “(d) DEPOSITS INTO ACCOUNT.—

12 “(1) MEDICAID TRANSFER.—There is hereby
13 transferred to the Account, from amounts appro-
14 priated for Grants to States for Medicaid, amounts
15 equivalent to the aggregate amount of the reductions
16 in payments under section 1903(a)(1) attributable to
17 the application of section 1935(c).

18 “(2) APPROPRIATIONS TO COVER GOVERNMENT
19 CONTRIBUTIONS.—There are authorized to be appro-
20 priated from time to time, out of any moneys in the
21 Treasury not otherwise appropriated, to the Ac-
22 count, an amount equivalent to the amount of pay-
23 ments made from the Account, reduced by—

24 “(1) the amount transferred to the Ac-
25 count under paragraph (1);

1 “(2) the beneficiary premiums collected
2 and credited to the account under section
3 2231(b)(2); and

4 “(3) fees collected and credited to the ac-
5 count under section 2233.

6 “SECONDARY PAYER PROVISIONS

7 “SEC. 2235. The provisions of section 1862(b) shall
8 apply to the benefits provided under this part.

9 “DEFINITIONS; TREATMENT OF REFERENCES TO
10 PROVISIONS IN MEDICARE+CHOICE PROGRAM

11 “SEC. 2236. (a) DEFINITIONS.—In this part:

12 “(1) COMMISSIONER.—The term ‘Commis-
13 sioner’ means the Commissioner of the Competitive
14 Medicare Agency.

15 “(2) COVERED OUTPATIENT DRUG.—

16 “(A) IN GENERAL.—Except as provided in
17 this subparagraph (B), the term ‘covered out-
18 patient drug’ means—

19 “(i) a drug that may be dispensed
20 only upon a prescription and that is de-
21 scribed in clause (i) or (ii) of section
22 1927(k)(2)(A); or

23 “(ii) a biological product or insulin de-
24 scribed in subparagraph (B) or (C) of such
25 section.

26 “(B) EXCLUSIONS.—

1 “(i) IN GENERAL.—The term ‘covered
2 outpatient drug’ does not include drugs or
3 classes of drugs, or their medical uses,
4 which may be excluded from coverage or
5 otherwise restricted under section
6 1927(d)(2), other than subparagraph (E)
7 thereof (relating to smoking cessation
8 agents).

9 “(ii) AVOIDANCE OF DUPLICATE COV-
10 ERAGE.—A drug prescribed for an indi-
11 vidual that would otherwise be a covered
12 outpatient drug under this part shall not
13 be so considered if payment for such drug
14 is available under part A or B of title
15 XVIII (but shall be so considered if such
16 payment is not available because benefits
17 under part A or B of title XVIII have been
18 exhausted), without regard to whether the
19 individual is entitled to benefits under such
20 part A or enrolled under such part B.

21 “(3) ELIGIBLE BENEFICIARY.—The term ‘eligi-
22 ble beneficiary’ means an individual that is entitled
23 to benefits under part A of title XVIII and enrolled
24 under part B of such title.

1 “(4) ELIGIBLE ENTITY.—The term ‘eligible en-
 2 tity’ means any risk-bearing entity that the Commis-
 3 sioner determines to be appropriate to provide eligi-
 4 ble beneficiaries with the benefits under a Medicare
 5 Prescription Plus plan, including—

6 “(A) a pharmaceutical benefit management
 7 company;

8 “(B) a wholesale or retail pharmacist deliv-
 9 ery system;

10 “(C) an insurer (including an insurer that
 11 offers medicare supplemental policies under sec-
 12 tion 1882);

13 “(D) another entity; or

14 “(E) any combination of the entities de-
 15 scribed in subparagraphs (A) through (D).

16 “(5) INITIAL COVERAGE LIMIT.—The term ‘ini-
 17 tial coverage limit’ means the limit as established
 18 under section 2225(d)(3), or, in the case of coverage
 19 that is not standard coverage, the comparable limit
 20 (if any) established under the coverage.

21 “(6) MEDICARE+CHOICE ORGANIZATION;
 22 MEDICARE+CHOICE PLAN.—The terms
 23 ‘Medicare+Choice organization’ and
 24 ‘Medicare+Choice plan’ have the meanings given
 25 such terms in subsections (a)(1) and (b)(1), respec-

tively, of section 1859 (relating to definitions relating to Medicare+Choice organizations and plans).

“(7) MEDICARE PRESCRIPTION DRUG ACCOUNT.—The term ‘Medicare Prescription Drug Account’ means the Medicare Prescription Drug Account established under section 2234 and located within the Federal Supplementary Medical Insurance Trust Fund established under section 1841.

“(8) MEDICARE PRESCRIPTION PLUS PLAN.—The term ‘Medicare Prescription Plus plan’ means a health benefits plan that the Commissioner has approved under section 2229.

“(9) STANDARD COVERAGE.—The term ‘standard coverage’ means the coverage described in section 2225(d).

“(b) APPLICATION OF MEDICARE+CHOICE PROVISIONS UNDER THIS PART.—For purposes of applying provisions of part C of title XVIII under this part with respect to a Medicare Prescription Plus plan and an eligible entity, unless otherwise provided in this part such provisions shall be applied as if—

“(1) any reference to a Medicare+Choice plan included a reference to a Medicare Prescription Plus plan;

1 “(2) any reference to a provider-sponsored or-
2 ganization included a reference to an eligible entity;

3 “(3) any reference to a contract under section
4 1857 included a reference to a contract under sec-
5 tion 2227(b); and

6 “(4) any reference to part C of title XVIII in-
7 cluded a reference to this part.”.

8 (b) SUBMISSION OF LEGISLATIVE PROPOSAL.—Not
9 later than 6 months after the date of enactment of this
10 Act, the Secretary of Health and Human Services and the
11 Commissioner of the Competitive Medicare Agency shall
12 submit to the appropriate committees of Congress a legis-
13 lative proposal providing for such technical and con-
14 forming amendments in the law as are required by the
15 provisions of this Act.

16 **SEC. 202. AMENDMENTS TO FEDERAL SUPPLEMENTARY**
17 **MEDICAL INSURANCE TRUST FUND.**

18 Section 1841 of the Social Security Act (42 U.S.C.
19 1395t) is amended—

20 (1) in the last sentence of subsection (a)—

21 (A) by striking “and” after “section
22 201(i)(1)”; and

23 (B) by inserting before the period the fol-
24 lowing: “, and such amounts as may be depos-
25 ited in, or appropriated to, the Medicare Pre-

1 scription Drug Account established by section
2 2234”;

3 (2) in subsection (g), by inserting after “by this
4 part,” the following: “the payments provided for
5 under the Prescription Drug and Supplemental Ben-
6 efit Program under part B of title XVIII (in which
7 case the payments shall come from the Medicare
8 Prescription Drug Account in the Supplementary
9 Medical Insurance Trust Fund),”;

10 (3) in the first sentence of subsection (h), by
11 inserting “(or the Commissioner of the Competitive
12 Medicare Agency by reason of section 2235 (in
13 which case the payments shall come from the Medi-
14 care Prescription Drug Account within such Trust
15 Fund))” after “Human Services”; and

16 (4) in the first sentence of subsection (i), by in-
17 serting “(or the Commissioner of the Competitive
18 Medicare Agency by reason of section 2235 (in
19 which case the payments shall come from the Medi-
20 care Prescription Drug Account within such Trust
21 Fund))” after “Human Services”.

1 **SEC. 203. PRESCRIPTION DRUG COVERAGE UNDER THE**
2 **MEDICARE+CHOICE PROGRAM.**

3 (a) IN GENERAL.—Section 1851 of the Social Secu-
4 rity Act (42 U.S.C. 1395w-21) is amended by adding at
5 the end the following new subsection:

6 “(j) AVAILABILITY OF PRESCRIPTION DRUG BENE-
7 FITS.—

8 “(1) IN GENERAL.—A Medicare+Choice orga-
9 nization may not offer prescription drug coverage
10 (other than that required under parts A and B) to
11 an enrollee under a Medicare+Choice plan unless
12 such drug coverage is at least qualified prescription
13 drug coverage and unless the requirements of this
14 subsection with respect to such coverage are met.

15 “(2) COMPLIANCE WITH ADDITIONAL BENE-
16 FICIARY PROTECTIONS.—With respect to the offer-
17 ing of qualified prescription drug coverage by a
18 Medicare+Choice organization under a
19 Medicare+Choice plan, the organization and plan
20 shall meet the requirements of section 2226, includ-
21 ing requirements relating to information dissemina-
22 tion and grievance and appeals, in the same manner
23 as they apply to an eligible entity and a Medicare
24 Prescription Plus plan under part B of title XXII.
25 The Commissioner of the Competitive Medicare
26 Agency shall waive such requirements to the extent

1 the Administrator determines that such require-
2 ments duplicate requirements otherwise applicable to
3 the organization or plan under this part.

4 “(3) TREATMENT OF COVERAGE.—Except as
5 provided in this subsection, qualified prescription
6 drug coverage offered under this subsection shall be
7 treated under this part in the same manner as sup-
8 plemental health care benefits described in section
9 1852(a)(3)(A).

10 “(4) AVAILABILITY OF COST-SHARING SUB-
11 SIDIES FOR LOW-INCOME ENROLLEES AND REINSUR-
12 ANCE SUBSIDY PAYMENTS FOR ORGANIZATIONS.—
13 For provisions—

14 “(A) providing cost-sharing subsidies to
15 low-income individuals receiving qualified pre-
16 scription drug coverage through a
17 Medicare+Choice plan, see section 2231; and

18 “(B) providing a Medicare+Choice organi-
19 zation with reinsurance subsidy payments for
20 providing qualified prescription drug coverage
21 under this part, see section 2232.

22 “(5) SPECIFICATION OF SEPARATE AND STAND-
23 ARD PREMIUM.—

24 “(A) IN GENERAL.—For purposes of ap-
25 plying section 1854 and determining the pre-

mium discount under section 2231(c) with respect to qualified prescription drug coverage offered under this subsection under a plan, the Medicare+Choice organization shall compute and publish the following:

“(i) SEPARATE PRESCRIPTION DRUG PREMIUM.—A premium for prescription drug benefits that constitutes qualified prescription drug coverage that is separate from other coverage under the plan.

“(ii) PORTION OF COVERAGE ATTRIBUTABLE TO STANDARD BENEFITS.—The ratio of the actuarial value of standard coverage to the actuarial value of the qualified prescription drug coverage offered under the plan.

“(iii) PORTION OF PREMIUM ATTRIBUTABLE TO STANDARD BENEFITS.—A standard premium equal to the product of the premium described in clause (i) and the ratio under clause (ii).

The premium under clause (i) shall be computed without regard to any reduction in the premium permitted under subparagraph (B).

“(B) REDUCTION OF PREMIUMS ALLOWED.—Nothing in this subsection shall be construed as preventing a Medicare+Choice organization from reducing the amount of a premium charged for prescription drug coverage because of the application of subsections (f)(1)(A) and (i)(2)(A) of section 1854 to other coverage.

“(6) TRANSITION IN INITIAL ENROLLMENT PERIOD.—Notwithstanding any other provision of this part, the annual, coordinated election period under subsection (e)(3)(B) for 2003 shall be the 6-month period beginning with November 2002.

“(7) QUALIFIED PRESCRIPTION DRUG COVERAGE; STANDARD COVERAGE.—For purposes of this part, the terms ‘qualified prescription drug coverage’ and ‘standard coverage’ have the meanings given such terms in section 2225.”.

(b) CONFORMING AMENDMENTS.—Section 1851(a)(1) of the Social Security Act (42 U.S.C. 1395w-21(a)(1)) is amended—

(1) by inserting “(other than qualified prescription drug benefits)” after “benefits”;

(2) by striking the period at the end of subparagraph (B) and inserting a comma; and

1 (3) by adding at the end the following flush lan-
2 guage:

3 “and may elect qualified prescription drug coverage
4 in accordance with part B of title XXII.”.

5 (c) EFFECTIVE DATE.—The amendments made by
6 this section apply to coverage provided on or after January
7 1, 2003.

8 **SEC. 204. MEDICAID AMENDMENTS.**

9 (a) DETERMINATIONS OF ELIGIBILITY FOR LOW-IN-
10 COME SUBSIDIES.—

11 (1) REQUIREMENT.—Section 1902 of the Social
12 Security Act (42 U.S.C. 1396a) is amended in sub-
13 section (a)—

14 (A) by striking “and” at the end of para-
15 graph (64);

16 (B) by striking the period at the end of
17 paragraph (65) and inserting “; and”; and

18 (C) by inserting after paragraph (65) the
19 following new paragraph:

20 “(66) provide for making eligibility determina-
21 tions under section 1935(a).”.

22 (2) NEW SECTION.—Title XIX of the Social Se-
23 curity Act (42 U.S.C. 1396 et seq.) is amended—

24 (A) by redesignating section 1935 as sec-
25 tion 1936; and

(B) by inserting after section 1934 the following new section:

“SPECIAL PROVISIONS RELATING TO MEDICARE

PRESCRIPTION DRUG BENEFIT

“SEC. 1935. (a) REQUIREMENT FOR MAKING ELIGIBILITY DETERMINATIONS FOR LOW-INCOME SUBSIDIES.—As a condition of its State plan under this title under section 1902(a)(66) and receipt of any Federal financial assistance under section 1903(a), a State shall—

“(1) make determinations of eligibility for premium and cost-sharing subsidies under (and in accordance with) section 2231;

“(2) inform the Commissioner of the Competitive Medicare Agency of such determinations in cases in which such eligibility is established; and

“(3) otherwise provide such Commissioner with such information as may be required to carry out part B of title XXII (including section 2231).

“(b) PAYMENTS FOR ADDITIONAL ADMINISTRATIVE COSTS.—

“(1) IN GENERAL.—The amounts expended by a State in carrying out subsection (a) are, subject to paragraph (2), expenditures reimbursable under the appropriate paragraph of section 1903(a); except that, notwithstanding any other provision of such section, the applicable Federal matching rates with

1 respect to such expenditures under such section shall
2 be increased as follows:

3 “(A) For expenditures attributable to costs
4 incurred during 2003, the otherwise applicable
5 Federal matching rate shall be increased by 20
6 percent of the percentage otherwise payable
7 (but for this subsection) by the State.

8 “(B) For expenditures attributable to costs
9 incurred during 2004, the otherwise applicable
10 Federal matching rate shall be increased by 40
11 percent of the percentage otherwise payable
12 (but for this subsection) by the State.

13 “(C) For expenditures attributable to costs
14 incurred during 2005, the otherwise applicable
15 Federal matching rate shall be increased by 60
16 percent of the percentage otherwise payable
17 (but for this subsection) by the State.

18 “(D) For expenditures attributable to costs
19 incurred during 2006, the otherwise applicable
20 Federal matching rate shall be increased by 80
21 percent of the percentage otherwise payable
22 (but for this subsection) by the State.

23 “(E) For expenditures attributable to costs
24 incurred after 2006, the otherwise applicable

1 Federal matching rate shall be increased to 100
2 percent.

3 “(2) COORDINATION.—The State shall provide
4 the Secretary with such information as may be nec-
5 essary to properly allocate administrative expendi-
6 tures described in paragraph (1) that may otherwise
7 be made for similar eligibility determinations.”.

8 (b) PHASED-IN FEDERAL ASSUMPTION OF MEDICAID
9 RESPONSIBILITY FOR PREMIUM AND COST-SHARING SUB-
10 SIDIES FOR DUALY ELIGIBLE INDIVIDUALS.—

11 (1) IN GENERAL.—Section 1903(a)(1) of the
12 Social Security Act (42 U.S.C. 1396b(a)(1)) is
13 amended by inserting before the semicolon the fol-
14 lowing: “, reduced by the amount computed under
15 section 1935(c)(1) for the State and the quarter”.

16 (2) AMOUNT DESCRIBED.—Section 1935 of the
17 Social Security Act, as inserted by subsection (a)(2),
18 is amended by adding at the end the following new
19 subsection:

20 “(c) FEDERAL ASSUMPTION OF MEDICAID PRE-
21 SCRIPTON DRUG COSTS FOR DUALY ELIGIBLE BENE-
22 FICIARIES.—

23 “(1) IN GENERAL.—For purposes of section
24 1903(a)(1), for a State that is 1 of the 50 States
25 or the District of Columbia for a calendar quarter

1 in a year (beginning with 2003) the amount com-
2 puted under this subsection is equal to the product
3 of the following:

4 “(A) MEDICARE SUBSIDIES.—The total
5 amount of payments made in the quarter under
6 section 2231 (relating to premium and cost-
7 sharing prescription drug subsidies for low-in-
8 come medicare beneficiaries) that are attrib-
9 utable to individuals who are residents of the
10 State and are entitled to benefits with respect
11 to prescribed drugs under the State plan under
12 this title (including such a plan operating under
13 a waiver under section 1115).

14 “(B) STATE MATCHING RATE.—A propor-
15 tion computed by subtracting from 100 percent
16 the Federal medical assistance percentage (as
17 defined in section 1905(b)) applicable to the
18 State and the quarter.

19 “(C) PHASE-OUT PROPORTION.—The
20 phase-out proportion (as defined in paragraph
21 (2)) for the quarter.

22 “(2) PHASE-OUT PROPORTION.—For purposes
23 of paragraph (1)(C), the ‘phase-out proportion’ for
24 a calendar quarter in—

25 “(A) 2003 is 90 percent;

1 “(B) 2004 is 80 percent;

2 “(C) 2005 is 70 percent;

3 “(D) 2006 is 60 percent; or

4 “(E) a year after 2006 is 50 percent.”.

5 (c) MEDICAID PROVIDING WRAP-AROUND BENE-
6 FITS.—Section 1935 of the Social Security Act, as so in-
7 serted and amended, is further amended by adding at the
8 end the following new subsection:

9 “(d) ADDITIONAL PROVISIONS.—

10 “(1) MEDICAID AS SECONDARY PAYOR.—In the
11 case of an individual dually entitled to qualified pre-
12 scription drug coverage under a Prescription Plus
13 Plan under part B of title XXII (or under a
14 Medicare+Choice plan under part C of such title)
15 and medical assistance for prescribed drugs under
16 this title, medical assistance shall continue to be pro-
17 vided under this title for prescribed drugs to the ex-
18 tent payment is not made under the Medicare Pre-
19 scription Plus plan or the Medicare+Choice plan se-
20 lected by the individual.

21 “(2) CONDITION.—A State may require, as a
22 condition for the receipt of medical assistance under
23 this title with respect to prescription drug benefits
24 for an individual eligible to obtain qualified prescrip-
25 tion drug coverage described in paragraph (1), that

1 the individual elect qualified prescription drug cov-
 2 erage under the program under part B of title
 3 XXII.”.

4 (d) TREATMENT OF TERRITORIES.—

5 (1) IN GENERAL.—Section 1935 of the Social
 6 Security Act, as so inserted and amended, is further
 7 amended—

8 (A) in subsection (a)(1), by inserting “sub-
 9 ject to subsection (e),” after “section 1903”;

10 (B) in subsection (c)(1), by inserting “sub-
 11 ject to subsection (e),” after “1903(a)”; and

12 (C) by adding at the end the following new
 13 subsection:

14 “(e) TREATMENT OF TERRITORIES.—

15 “(1) IN GENERAL.—In the case of a State,
 16 other than the 50 States and the District of
 17 Columbia—

18 “(A) the previous provisions of this section
 19 shall not apply to residents of such State; and

20 “(B) if the State establishes a plan de-
 21 scribed in paragraph (2) (for providing medical
 22 assistance with respect to the provision of pre-
 23 scription drugs to medicare beneficiaries), the
 24 amount otherwise determined under section
 25 1108(f) (as increased under section 1108(g))

for the State shall be increased by the amount specified in paragraph (3).

“(2) PLAN.—The plan described in this paragraph is a plan that—

“(A) provides medical assistance with respect to the provision of covered outpatient drugs (as defined in section 2236(2)) to low-income medicare beneficiaries; and

“(B) assures that additional amounts received by the State that are attributable to the operation of this subsection are used only for such assistance.

“(3) INCREASED AMOUNT.—

“(A) IN GENERAL.—The amount specified in this paragraph for a State for a year is equal to the product of—

“(i) the aggregate amount specified in subparagraph (B); and

“(ii) the amount specified in section 1108(g)(1) for that State, divided by the sum of the amounts specified in such section for all such States.

“(B) AGGREGATE AMOUNT.—The aggregate amount specified in this subparagraph for—

1 “(i) 2003, is equal to \$20,000,000; or

2 “(ii) a subsequent year, is equal to the
3 aggregate amount specified in this sub-
4 paragraph for the previous year increased
5 by the annual percentage increase specified
6 in section 2225(d)(5) for the year involved.

7 “(4) REPORT.—The Secretary shall submit to
8 Congress a report on the application of this sub-
9 section and may include in the report such rec-
10 ommendations as the Secretary deems appropriate.”.

11 (2) CONFORMING AMENDMENT.—Section
12 1108(f) of the Social Security Act (42 U.S.C.
13 1308(f)) is amended by inserting “and section
14 1935(e)(1)(B)” after “Subject to subsection (g)”.

15 **SEC. 205. MEDIGAP PROVISIONS.**

16 (a) IN GENERAL.—Notwithstanding any other provi-
17 sion of law, no new medicare supplemental policy that pro-
18 vides coverage of expenses for prescription drugs may be
19 issued under section 1882 of the Social Security Act on
20 or after January 1, 2003, to an individual unless it re-
21 places a medicare supplemental policy that was issued to
22 that individual and that provided some coverage of ex-
23 penses for prescription drugs.

(b) ISSUANCE OF SUBSTITUTE POLICIES IF OBTAIN-
ING PRESCRIPTION DRUG COVERAGE THROUGH MEDI-
CARE.—

(1) IN GENERAL.—The issuer of a medicare
supplemental policy—

(A) may not deny or condition the issuance
or effectiveness of a medicare supplemental pol-
icy that has a benefit package classified as “A”,
“B”, “C”, “D”, “E”, “F”, or “G” (under the
standards established under subsection (p)(2) of
section 1882 of the Social Security Act (42
U.S.C. 1395ss)) and that is offered and is
available for issuance to new enrollees by such
issuer;

(B) may not discriminate in the pricing of
such policy, because of health status, claims ex-
perience, receipt of health care, or medical con-
dition; and

(C) may not impose an exclusion of bene-
fits based on a preexisting condition under such
policy,

in the case of an individual described in paragraph
(2) who seeks to enroll under the policy not later
than 63 days after the date of the termination of en-
rollment described in such paragraph and who sub-

1 mits evidence of the date of termination or
2 disenrollment along with the application for such
3 medicare supplemental policy.

4 (2) INDIVIDUAL COVERED.—An individual de-
5 scribed in this paragraph is an individual who—

6 (A) enrolls in a Medicare Prescription Plus
7 plan under part B of title XXII of the Social
8 Security Act (as added by section 201); and

9 (B) at the time of such enrollment was en-
10 rolled and terminates enrollment in a medicare
11 supplemental policy which has a benefit pack-
12 age classified as “H”, “I”, or “J” under the
13 standards referred to in paragraph (1)(A) or
14 terminates enrollment in a policy to which such
15 standards do not apply but which provides ben-
16 efits for prescription drugs.

17 (3) ENFORCEMENT.—The provisions of para-
18 graph (1) shall be enforced as though such provi-
19 sions were included in section 1882(s) of the Social
20 Security Act (42 U.S.C. 1395ss(s)).

21 (4) DEFINITIONS.—For purposes of this sub-
22 section, the term “medicare supplemental policy”
23 has the meaning given such term in section 1882(g)
24 of the Social Security Act (42 U.S.C. 1395ss(g)).

1 (c) MEDIGAP PROTECTIONS FOR INDIVIDUALS WHO
 2 LOSE MEDICARE PRESCRIPTION PLUS PLAN COV-
 3 ERAGE.—Section 1882 of the Social Security Act (42
 4 U.S.C. 1395ss) is amended—

5 (1) in subsection (d)(3)—

6 (A) in subparagraph (A), by adding at the
 7 end the following:

8 “(ix) Nothing in this subparagraph shall be construed
 9 as preventing the sale of 1 medicare supplemental policy
 10 and 1 Medicare Prescription Plus plan to an individual,
 11 except that the sale of such a policy or plan may not dupli-
 12 cate any health benefits under any policy or plan owned
 13 by the individual.”; and

14 (B) in subparagraph (B)(iii)—

15 (i) in subclause (I), by striking “(II)
 16 and (III)” and inserting “(II), (III), and
 17 (IV)”;

18 (ii) by redesignating subclause (III) as
 19 subclause (IV); and

20 (iii) by inserting after subclause (II)
 21 the following:

22 “(III) If the statement required by clause (i) is ob-
 23 tained and indicates that the individual is enrolled in 1
 24 medicare supplemental policy or 1 Medicare Prescription
 25 Plus plan, the sale of another policy or plan is not in viola-

tion of clause (i) if such other policy or plan does not duplicate health benefits under the policy or plan in which the individual is enrolled.”;

(2) in subsection (g)(1), by inserting “, Medicare Prescription Plus plan,” after “Medicare+Choice plan”; and

(3) in subsection (s)(3)—

(A) in subparagraph (B)—

(i) in clause (ii), by inserting “is enrolled with an eligible entity under a Medicare Prescription Plus plan under part B of title XXII or” after “section 1851(e)(4) or the individual”;

(ii) in clause (v)(II), by inserting “with any eligible entity under a Medicare Prescription Plus plan under part B of title XXII,” after “under part C,”; and

(iii) in clause (vi), by inserting “, in a Medicare Prescription Plus plan under part B of title XXII,” after “under part C”; and

(B) in subparagraph (E)—

(i) in clause (i), by inserting “(or, in the case of an individual enrolled under a Medicare Prescription Plus plan, the date

on which the individual was notified by the eligible entity of the impending termination or discontinuance of the Medicare Prescription Plus plan) after “it offers in the area”; and

(ii) in clause (ii), by inserting “or Medicare Prescription Plus plan” after “Medicare+Choice plan”.

**SEC. 206. GAO REPORT ON PART B PAYMENT FOR DRUGS
AND BIOLOGICALS AND RELATED SERVICES.**

(a) IN GENERAL.—The Comptroller General of the United States shall conduct a study to quantify the extent to which reimbursement for drugs and biologicals under the current medicare payment methodology (provided under section 1842(o) of the Social Security Act (42 U.S.C. 1395u(o)) overpays for the cost of such drugs and biologicals compared to the average acquisition cost paid by physicians or other suppliers of such drugs.

(b) ELEMENTS.—The study shall also assess the consequences of changing the current medicare payment methodology to a payment methodology that is based on the average acquisition cost of the drugs. The study shall, at a minimum, assess the effects of such a reduction on—

(1) the delivery of health care services to medicare beneficiaries with cancer;

1 (2) total medicare expenditures, including an
2 estimate of the number of patients who would, as a
3 result of the payment reduction, receive chemo-
4 therapy in a hospital rather than in a physician's of-
5 fice;

6 (3) the delivery of dialysis services;

7 (4) the delivery of vaccines;

8 (5) the administration in physician offices of
9 drugs other than cancer therapy drugs; and

10 (6) the effect on the delivery of drug therapies
11 by hospital outpatient departments of changing the
12 average wholesale price as the basis for medicare
13 pass-through payments to such departments, as in-
14 cluded in the Medicare, Medicaid, and SCHIP Bal-
15 anced Budget Refinement Act of 1999.

16 (c) PAYMENT FOR RELATED PROFESSIONAL SERV-
17 ICES.—The study shall also include a review of the extent
18 to which other payment methodologies under part B of
19 the medicare program, if any, intended to reimburse phy-
20 sician and other suppliers of drugs and biologicals de-
21 scribed in subsection (a) for costs incurred in handling,
22 storing, and administering such drugs and biologicals are
23 inadequate to cover such costs and whether an additional
24 payment would be required to cover these costs under the
25 average acquisition cost methodology.

(d) CONSIDERATION OF ISSUES IN IMPLEMENTING AN AVERAGE ACQUISITION COST METHODOLOGY.—The study shall assess possible means by which a payment method based on average acquisition cost could be implemented, including at least the following:

(1) Identification of possible bases for determining the average acquisition cost of drugs, such as surveys of wholesaler catalog prices, and determination of the advantages, disadvantages, and costs (to the government and the public) of each possible approach.

(2) The impact on individual providers and practitioners if average or median prices are used as the payment basis.

(3) Methods for updating and keeping current the prices used as the payment basis.

(e) COORDINATION WITH BBRA STUDY.—The Comptroller General of the United States shall conduct the study under this section in coordination with the study provided for under section 213(a) of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (113 Stat. 1501A–350), as enacted into law by section 1000(a)(6) of Public Law 106–113.

(f) REPORT.—Not later than 6 months after the date of enactment of this Act, the Comptroller General of the

1 United States shall submit to Congress a report on the
 2 study conducted under this section, as well as the study
 3 referred to in subsection (e). Such report shall include rec-
 4 ommendations regarding such changes in the medicare re-
 5 imbursement policies described in subsections (a) and (c)
 6 as the Comptroller General deems appropriate, as well as
 7 the recommendations described in section 213(b) of the
 8 Medicare, Medicaid, and SCHIP Balanced Budget Refine-
 9 ment Act of 1999.

10 **TITLE III—MEDICARE+CHOICE** 11 **REFORMS**

12 **SEC. 301. INCREASE IN NATIONAL PER CAPITA** 13 **MEDICARE+CHOICE GROWTH PERCENTAGE** 14 **IN 2001 AND 2002.**

15 Section 1853(c)(6)(B) of the Social Security Act (42
 16 U.S.C. 1395w-23(c)(6)(B)) is amended—

- 17 (1) by striking clauses (iv) and (v);
- 18 (2) by redesignating clause (vi) as clause (iv);
- 19 and
- 20 (3) in clause (iv) (as so redesignated), by strik-
 21 ing “2002” and inserting “2000”.

22 **SEC. 302. REMOVING APPLICATION OF BUDGET NEU-** 23 **TRALITY BEGINNING IN 2002.**

24 Section 1853(c) of the Social Security Act (42 U.S.C.
 25 1395w-23(c)) is amended—

(1) in paragraph (1)(A), in the matter following clause (ii), by inserting “(for years other than 2002)” after “multiplied”; and

(2) in paragraph (5), by inserting “(other than 2002)” after “for each year”.

SEC. 303. MEDICARE+CHOICE COMPETITION PROGRAM.

(a) PAYMENTS TO MEDICARE+CHOICE ORGANIZATIONS BASED ON RISK-ADJUSTED BIDS.—

(1) MONTHLY PAYMENTS.—Section 1853(a)(1)(A) of the Social Security Act (42 U.S.C. 1395w–23(a)(1)(A)) is amended by adding at the end the following new sentences: “For each year (beginning with 2003), under a contract under section 1857, the Commissioner shall make to each Medicare+Choice organization, with respect to coverage of an individual for a month under this part in a Medicare+Choice payment area, monthly payments with respect to benefits under parts A and B combined in accordance with subsection (c)(8). For rules relating to payment of the Medicare+Choice monthly supplemental beneficiary premium or any prescription drug premium, see section 1854(j).”.

(2) ANNUAL DETERMINATION AND ANNOUNCEMENT OF PAYMENT FACTORS.—

1 (A) IN GENERAL.—Section 1853(b) (42
2 U.S.C. 1395w-23(b)) is amended—

3 (i) in paragraph (1), by striking “the
4 calendar year concerned” and all that fol-
5 lows and inserting “the calendar year con-
6 cerned with respect to each
7 Medicare+Choice payment area, the fol-
8 lowing:

9 “(A) The benchmark amount (as defined
10 in paragraph (5)(A)).

11 “(B) The county-specific monthly per cap-
12 ita costs (as defined in paragraph (5)(B)).

13 “(C) The demographic adjustment factors
14 to be used in making payment for individual en-
15 rollees (as defined in paragraph (5)(C)).

16 “(D) The ESRD adjustment (as defined in
17 paragraph (5)(D)).

18 “(E) The health status adjustment (as de-
19 fined in paragraph (5)(E)).”.

20 (ii) in paragraph (3), by striking
21 “monthly adjusted” and all that follows be-
22 fore the period at the end and inserting
23 “the payment rates under this part for
24 each individual enrolled in the
25 Medicare+Choice plan offered by the

1 Medicare+Choice organization for the
2 year”; and

3 (iii) by adding at the end the fol-
4 lowing new paragraph:

5 “(5) DEFINITIONS RELATING TO FACTORS
6 USED IN ADJUSTING BIDS FOR MEDICARE+CHOICE
7 ORGANIZATIONS AND IN DETERMINING ENROLLEE
8 PREMIUMS.—In this part:

9 “(A) BENCHMARK AMOUNT.—

10 “(i) IN GENERAL.—The term ‘bench-
11 mark amount’ means, for a payment area,
12 an amount equal to the greater of—

13 “(I) except as provided in clause
14 (ii), $\frac{1}{12}$ of the annual
15 Medicare+Choice capitation rate that
16 would have applied in that payment
17 area under paragraphs (1) through
18 (7) of subsection (c); or

19 “(II) the county-specific monthly
20 per capita costs for such area.

21 “(ii) PHASE-OUT OF MINIMUM
22 AMOUNT AND BLENDED CAPITATION
23 RATE.—If the amount calculated under
24 clause (i)(I) for a year for all payment
25 areas is equal to either the minimum

1 amount or the blended capitation rate, for
 2 all subsequent years the Commissioner
 3 shall not calculate the rates described in
 4 that clause and the amount under such
 5 clause instead shall be equal to the county-
 6 specific monthly per capita costs.

7 “(B) COUNTY-SPECIFIC MONTHLY PER
 8 CAPITA COSTS.—

9 “(i) IN GENERAL.—Subject to clause
 10 (ii), the term ‘county-specific monthly per
 11 capita costs’ means the amount of payment
 12 in a Medicare+Choice payment area for
 13 benefits under this title and associated
 14 claims processing costs for individuals enti-
 15 tled to benefits under part A and individ-
 16 uals enrolled in the program under part B
 17 who are not enrolled in a Medicare+Choice
 18 plan under this part. The Commissioner
 19 shall determine such amount in a manner
 20 similar to the manner in which the Sec-
 21 retary determined the adjusted average per
 22 capita cost under section 1876, except that
 23 such determination shall include in such
 24 amount any amounts that would have been
 25 paid under this title if individuals entitled

1 to benefits under this title had not received
2 services from facilities of the Department
3 of Veterans Affairs or the Department of
4 Defense.

5 “(ii) EXCLUSION OF GME COSTS.—

6 The calculation of costs under clause (i)
7 shall not take into account any amounts
8 attributable to—

9 “(I) payments for costs of grad-
10 uate medical education under section
11 1886(h); or

12 “(II) payments for indirect costs
13 of medical education under section
14 1886(d)(5)(B).

15 “(C) DEMOGRAPHIC ADJUSTMENT FAC-
16 TORS.—The term ‘demographic adjustment fac-
17 tors’ means such factors as age, disability sta-
18 tus, gender, and institutional status, so as to
19 ensure actuarial equivalence. The Commissioner
20 may add to, modify, or substitute for such fac-
21 tors, if such changes will improve the deter-
22 mination of actuarial equivalence, and in that
23 event the Commissioner will make comparable
24 adjustments to the benchmark amounts.

1 “(D) ESRD ADJUSTMENT FACTOR.—The
2 term ‘ESRD adjustment factor’ means the ad-
3 justment established by the Commissioner
4 under section 1851(a)(3)(B) that applies with
5 respect to enrolled individuals who have end-
6 stage renal disease.

7 “(E) HEALTH STATUS ADJUSTMENT FAC-
8 TOR.—The term ‘health status adjustment fac-
9 tor’ means the health status adjustment imple-
10 mented under subsection (a)(3)(C) until such
11 time as the Commissioner develops a health sta-
12 tus adjustment factor that takes into account
13 the specific health care needs of
14 Medicare+Choice eligible individuals who do
15 not have end-stage renal disease based on the
16 delivery of care in all settings, which method-
17 ology shall be phased in equally over a 10-year
18 period, beginning with 2004, or (if later) the
19 date on which such factor is developed.

20 (3) SUBMISSION OF BIDS BY
21 MEDICARE+CHOICE ORGANIZATIONS.—Section
22 1854(a) of the Social Security Act (42 U.S.C.
23 1395w-24(a)) is amended—

(A) in paragraph (1), by striking “Not later than July 1” and inserting “Subject to paragraph (6), not later than July 1”; and

(B) by adding at the end the following:

“(6) SUBMISSION OF BIDS BY
MEDICARE+CHOICE ORGANIZATIONS.—

“(A) IN GENERAL.—For each year (beginning with 2003), each Medicare+Choice organization shall submit to the Commissioner, in a form and manner specified by the Commissioner and for each Medicare+Choice plan which it intends to offer in a service area in the following year—

“(i) notice of such intent and information on the service area and plan type for each plan;

“(ii) the information described in paragraph (2) for the type of plan involved; and

“(iii) the enrollment capacity (if any) in relation to the plan and area.

“(B) INFORMATION REQUIRED FOR COMPETITIVE PLANS.—The information described in this paragraph is as follows:

1 “(i) The monthly plan bid for the pro-
2 vision of benefits.

3 “(ii) The actuarial value of the reduc-
4 tion in cost-sharing for benefits under
5 parts A and B included in each plan bid
6 and a description of the cost-sharing for
7 such benefits.

8 “(iii) The actuarial value of any addi-
9 tional benefits required under subsection
10 (i), a description of cost-sharing for such
11 benefits, and such other information as the
12 Commissioner considers necessary.

13 “(iv) The actuarial value of any sup-
14 plemental benefits, the monthly supple-
15 mental premium (if any) for such benefits,
16 a description of any cost-sharing for such
17 benefits, and such other information as the
18 Commissioner considers necessary.

19 “(v) For each Medicare+Choice pay-
20 ment area, the assumptions used with re-
21 spect to the number of—

22 “(I) enrolled individuals who are
23 entitled to benefits under parts A and
24 enrolled under part B who do not
25 have end-stage renal disease; and

1 “(II) such enrolled individuals
2 who have end-stage renal disease.”.

3 (4) COMMISSIONER’S DETERMINATION OF PAY-
4 MENT AMOUNT.—Section 1853(c) of the Social Se-
5 curity Act (42 U.S.C. 1395w–23(c)) is amended—

6 (A) in paragraph (1), by striking “subject
7 to paragraphs (6)(C) and (7)” and inserting
8 “subject to paragraphs (6)(C), (7), and (8)”;

9 (B) by adding at the end the following new
10 paragraph:

11 “(8) COMMISSIONER’S DETERMINATION OF PAY-
12 MENT AMOUNT.—

13 “(A) ADJUSTMENT OF BIDS.—The Com-
14 missioner shall adjust plan bids submitted
15 under section 1854(a)(6) based on the demo-
16 graphic adjustment factors, the ESRD adjust-
17 ment factor, and the health status adjustment
18 factor (as defined in subparagraphs (C), (D),
19 and (E), respectively, of subsection (b)(5)).

20 “(B) DETERMINATION OF BENCHMARK
21 PER COUNTY.—For each year (beginning with
22 2003), the Commissioner shall determine the
23 benchmark amount (as defined in subparagraph
24 (A) of subsection (b)(5)) for each
25 Medicare+Choice payment area and shall ad-

1 just such amount based on the demographic ad-
 2 justment factors, the ESRD adjustment factor,
 3 and the health status adjustment factor (as de-
 4 fined in subparagraphs (C), (D), and (E), re-
 5 spectively, of such section).

6 “(C) COMPARISON TO PLAN BENCHMARK
 7 AMOUNT.—

8 “(i) IN GENERAL.—The Commissioner
 9 shall compare the organization’s bid (as
 10 adjusted under subparagraph (A)) to the
 11 benchmark amount (as adjusted under
 12 subparagraph (B)) to determine the pay-
 13 ment amount under clause (ii).

14 “(ii) DETERMINATION OF PAYMENT
 15 AMOUNT.—The Commissioner shall deter-
 16 mine the monthly payment to a
 17 Medicare+Choice organization with respect
 18 to each individual enrolled in a
 19 Medicare+Choice plan as follows:

20 “(I) IF BID DOES NOT EXCEED
 21 BENCHMARK.—If the
 22 Medicare+Choice organization’s bid
 23 (as adjusted under subparagraph (A))
 24 does not exceed the benchmark
 25 amount (as adjusted under subpara-

graph (B)), the monthly payment shall be the benchmark amount, adjusted to account for the demographic adjustment factors, health status adjustment factor, and (if applicable) the ESRD adjustment factor of the individual enrollee, minus 25 percent of the difference between the bid and the benchmark amount determined under section 1854(i)(2)(A).

“(II) IF BID EXCEEDS BENCHMARK.—If the organization’s bid (as adjusted under subparagraph (A)) exceeds the benchmark amount (as adjusted under subparagraph (B)), the monthly payment shall be the bid, adjusted to account for the demographic adjustment factors, health status adjustment factor, and (if applicable) the ESRD adjustment factor of the individual enrollee.”.

(b) PREMIUMS.—

(1) DETERMINATION OF PREMIUM AMOUNT.—

Section 1854 of the Social Security Act (42 U.S.C.

1 1395w-24) is amended by adding at the end the fol-
2 lowing new subsections:

3 “(i) DETERMINATION OF MEDICARE PREMIUM RE-
4 DUCTION AND MEDICARE+CHOICE MONTHLY SUPPLE-
5 MENTAL BENEFICIARY PREMIUM.—

6 “(1) IN GENERAL.—Notwithstanding subsection
7 (b) and subject to paragraph (2), for each year (be-
8 ginning with 2003), the Commissioner shall deter-
9 mine the difference between the organization’s bid
10 (submitted under subsection (a)(6) and adjusted
11 under section 1853(c)(8)(A)) and the plan’s bench-
12 mark amount (as adjusted under 1853(c)(8)(B)) to
13 determine the amount of any medicare premium re-
14 duction, prescription drug premium reduction, re-
15 duction in plan cost-sharing, or additional benefits
16 required under paragraph (2)(A), or the
17 Medicare+Choice monthly supplemental beneficiary
18 premium for plan enrollees.

19 “(2) ADJUSTMENT.—

20 “(A) BIDS BELOW THE BENCHMARK.—

21 Notwithstanding subsection (f), if the organiza-
22 tion’s bid is lower than the plan’s benchmark
23 amount, 75 percent of the difference deter-
24 mined under paragraph (1) shall be returned to

the enrollee in the form of, at the option of the organization offering the plan—

“(i) a monthly medicare premium reduction for individuals enrolled in the plan (up to the entire amount of the premium for part B);

“(ii) a prescription drug premium reduction pursuant to subsection (j)(5)(B);

“(iii) a reduction in the actuarial value of plan cost-sharing for plan enrollees;

“(iv) such additional benefits as the organization may specify; or

“(v) any combination of the reductions and benefits described in clauses (i) through (iv).

“(B) BIDS ABOVE THE BENCHMARK.—If the organization’s bid is higher than the benchmark amount, the difference determined under paragraph (1) shall be the Medicare+Choice monthly supplemental beneficiary premium for individuals enrolled in the plan.

“(j) RULES RELATING TO PREMIUMS OWED BY MEDICARE+CHOICE ENROLLEES.—In the case of any Medicare+Choice monthly supplemental beneficiary pre-

1 mium under subsection (i)(2)(B) or any prescription drug
 2 premium under section 1851(j) that an individual is re-
 3 sponsible for under a Medicare+Choice plan in which the
 4 individual is enrolled, the following rules shall apply:

5 “(1) COMMISSIONER SHALL PAY THE DRUG
 6 PREMIUM TO THE ENTITY.—

7 “(A) IN GENERAL.—The Commissioner
 8 shall pay to the Medicare+Choice organization
 9 offering the Medicare+Choice plan the full
 10 amount of the prescription drug premium under
 11 section 1851(j) that the individual is respon-
 12 sible for under the plan.

13 “(B) PAYMENTS FROM MEDICARE PRE-
 14SCRIPTION DRUG ACCOUNT.—Payments under
 15 subparagraph (A) shall be made from the Medi-
 16 care Prescription Drug Account within the Fed-
 17 eral Supplementary Medical Insurance Trust
 18 Fund under section 1841.

19 “(2) PREMIUM DISCOUNT FOR DRUG BENE-
 20 FITS.—Subject to paragraph (4), the individual shall
 21 be entitled to the premium discount for prescription
 22 drugs determined under section 2231.

23 “(3) COLLECTION OF SUPPLEMENTAL AND
 24 DRUG PREMIUMS IN SAME MANNER AS PART B PRE-
 25 MIUM.—

1 “(A) SUPPLEMENTAL PREMIUM.—The
2 amount of any Medicare+Choice monthly sup-
3 plemental beneficiary premium that an indi-
4 vidual is responsible for under the plan shall be
5 collected and credited to the Federal Hospital
6 Insurance Trust Fund and the Federal Supple-
7 mentary Medical Insurance Trust Fund—

8 “(i) in such proportion as the Com-
9 missioner determines appropriate; and

10 “(ii) in the same manner as the
11 monthly premium determined under sec-
12 tion 1839 is collected and credited to the
13 Federal Supplementary Medical Insurance
14 Trust Fund under section 1840.

15 “(B) DRUG PREMIUM.—Subject to the ap-
16 plication of the premium discounts available
17 under section 2231, the amount of any pre-
18 mium drug premium that an individual is re-
19 sponsible for under the plan shall be collected
20 and credited to the Medicare Prescription Drug
21 Account within the Federal Supplementary
22 Medical Insurance Trust Fund under section
23 1841 in the same manner as the monthly pre-
24 mium determined under section 1839 is col-
25 lected and credited to the Federal Supple-

1 mentary Medical Insurance Trust Fund under
2 section 1840.

3 “(C) INFORMATION NECESSARY FOR COL-
4 LECTION.—In order to carry out subparagraph
5 (A), the Commissioner shall transmit to the
6 Commissioner of Social Security—

7 “(i) at the beginning of each year, the
8 name, social security account number, and
9 the Medicare+Choice monthly supple-
10 mental beneficiary premium and prescrip-
11 tion drug premium owed by the individual
12 for each month during the year; and

13 “(ii) periodically throughout the year,
14 information to update the information pre-
15 viously transmitted under this paragraph
16 for the year.

17 “(4) DISCOUNT REDUCED IF GREATER THAN
18 COMBINED PREMIUMS.—In the case of an individual
19 whose premium discount determined under section
20 2231(b) is equal to or less than the sum of any the
21 Medicare+Choice monthly supplemental beneficiary
22 premium and any prescription drug premium (after
23 any reduction described in section 1851(j)(5)(B)) for
24 the Medicare+Choice plan in which the individual is

enrolled, the premium subsidy shall be deemed to be an amount equal to such sum.”.

(2) LIMITATION ON ENROLLEE LIABILITY FOR SUPPLEMENTAL BENEFITS.—Section 1854(e)(2) of the Social Security Act (42 U.S.C. 1395w-24(e)(2)) is amended by striking “If the Medicare+Choice organization” and inserting “Except as provided in subsection (i)(2)(B), if the Medicare+Choice organization”.

(c) ALLOWING PLANS TO INCLUDE REDUCTIONS AND OTHER BENEFITS IN THEIR BASIC BENEFITS.—Section 1852(a)(1)(B) of the Social Security Act (42 U.S.C. 1395w-22(a)(1)) is amended—

(1) by inserting “(i)” after “(B)”;

(2) by adding at the end the following new clause:

“(ii) for 2003 and each subsequent year, at plan option, the reductions and benefits described in section 1854(i)(2)(A).”.

(d) TRANSITION TO ESRD ELIGIBILITY.—Section 1851(a)(3)(B) of the Social Security Act (42 U.S.C. 1395w-21(a)(3)(B)) is amended by inserting “until such time as the Commissioner establishes an ESRD adjustment factor that takes into account the specific health care needs of such individuals based on a delivery of care

1 in all settings (to be phased-in in such manner as the
 2 Commissioner deems appropriate)” after “determined to
 3 have end-stage renal disease”.

4 (e) CONFORMING AMENDMENTS.—

5 (1) PREMIUM REDUCTIONS UNDER PART B.—

6 (A) AMOUNT OF PREMIUMS.—Section
 7 1839(a)(2) of the Social Security Act (42
 8 U.S.C. 1395r(a)(2)) is amended by striking
 9 “shall” and all that follows and inserting the
 10 following: “shall be the amount determined
 11 under paragraph (3), adjusted as required in
 12 accordance with subsections (b), (c), and (f),
 13 and thereafter further modified as required to
 14 comply with section 1854(i)(2)(A).”.

15 (B) PAYMENT OF PREMIUMS.—Section
 16 1840 of the Social Security Act (42 U.S.C.
 17 1395s) is amended by adding at the end the fol-
 18 lowing new clause:

19 “(i) The Commissioner shall provide for necessary
 20 adjustments of the medicare premium for
 21 Medicare+Choice enrollees determined under section
 22 1854(i)(2)(A)(i). This premium adjustment may be pro-
 23 vided directly or as an adjustment to Social Security, Rail-
 24 road Retirement and Civil Service Retirement benefits, as
 25 appropriate, as the Commissioner of the Competitive

1 Medicare Agency determines feasible with the concurrence
2 of such agencies.”.

3 (2) APPROPRIATIONS FOR GOVERNMENT CON-
4 TRIBUTION.—Section 1844(a)(1) of the Social Secu-
5 rity Act (42 U.S.C. 1395w(a)(1)) is amended by
6 adding at the end the following new subparagraph:

7 “(C) an adjustment for the Government con-
8 tribution to reflect the savings to the Trust Fund
9 from enrollment in Medicare+Choice plans by bene-
10 ficiaries who receive monthly medicare premium re-
11 ductions in accordance with section 1854(i)(2)(A)(i);
12 plus”.

13 (3) CONTINUATION OF ENROLLMENT PER-
14 MITTED.—Section 1851(b)(1)(B) of the Social Secu-
15 rity Act (42 U.S.C. 1395w-21(b)(1)(B)) is amended
16 by striking “section 1852(a)(1)(A)” and inserting
17 “section 1852(a)(1)”.

18 (4) INFORMATION COMPARING PLAN PRE-
19 MIUMS.—Section 1851(d)(4)(B) of the Social Secu-
20 rity Act (42 U.S.C. 1395w-21(d)(4)(B)) is
21 amended—

22 (A) by striking “PREMIUMS.—The” and in-
23 serting “PREMIUMS.—

24 “(i) IN GENERAL.—The”;

1 (B) by adding at the end the following new
 2 clause:

3 “(ii) REDUCTIONS.—The reduction in
 4 the part B premiums, if any.”.

5 (5) NATIONAL COVERAGE DETERMINATIONS.—
 6 Section 1852(a)(5) of the Social Security Act (42
 7 U.S.C. 1395w–22(a)(5)) is amended by inserting
 8 “(or, for 2003 and each subsequent fiscal year, the
 9 county-specific monthly per capita costs)” after “the
 10 annual Medicare+Choice capitation rate”.

11 (6) DISCLOSURE REQUIREMENTS.—Section
 12 1852(c)(1)(F) of the Social Security Act (42 U.S.C.
 13 1395w–22(c)(1)(F)) is amended by striking clause
 14 (i) and redesignating clauses (ii) and (iii) as clauses
 15 (i) and (ii), respectively.

16 (7) GEOGRAPHIC ADJUSTMENT.—Section
 17 1853(d)(3)(B) of the Social Security Act (42 U.S.C.
 18 1395w–23(e)(3)(B)) is amended—

19 (A) in the heading, by striking “BUDGET
 20 NEUTRALITY”;

21 (B) by striking “adjust the payment rates”
 22 and all that follows through “that would have
 23 been made” and inserting “adjust the bench-
 24 mark amounts otherwise established under this
 25 section for Medicare+Choice payment areas in

the State in a manner so that the weighted average of the benchmark amounts under this section in the State equals the weighted average of benchmark amounts that would have been applicable”.

(8) MEDICARE+CHOICE MONTHLY BASIC BENEFICIARY PREMIUM.—Section 1854(b)(2)(A) of the Social Security Act (42 U.S.C. 1395w-24(b)(2)(A)) is amended by striking “the amount authorized to be charged” and all that follows and inserting “the amount required to be charged for the plan.”.

(9) COMMISSIONER DEFINED.—Section 1859(a) of the Social Security Act (42 U.S.C. 1395w-28(a)) is amended by adding at the end the following new paragraph:

“(3) COMMISSIONER.—The term ‘Commissioner’ means the Commissioner of the Competitive Medicare Agency appointed under section 2202(a)(1).”.

(f) INCLUSION OF COSTS OF VA AND DOD MILITARY FACILITY SERVICES TO MEDICARE-ELIGIBLE BENEFICIARIES.—Section 1853(c) of the Social Security Act (42 U.S.C. 1395w-23(c)) (as amended by subsection (a)(4)) is amended by adding at the end the following new paragraph:

1 “(9) INCLUSION OF COSTS OF VA AND DOD
2 MILITARY FACILITY SERVICES TO MEDICARE-ELIGI-
3 BLE BENEFICIARIES.—For purposes of determining
4 the blended capitation rate under subparagraph (A)
5 of paragraph (1) and the minimum percentage in-
6 crease under subparagraph (C) of such paragraph
7 for a year, the annual per capita rate of payment for
8 1997 determined under section 1876(a)(1)(C) shall
9 be adjusted to include in such rate the Commis-
10 sioner’s estimate, on a per capita basis, of the
11 amount of additional payments that would have been
12 made in the area involved under this title if individ-
13 uals entitled to benefits under this title had not re-
14 ceived services from facilities of the Department of
15 Veterans Affairs or the Department of Defense.”.

16 (g) EFFECTIVE DATE.—The amendments made by
17 this section shall take effect on January 1, 2003.

18 **SEC. 304. FREEZE OF HEALTH RISK ADJUSTER AT 20 PER-**
19 **CENT.**

20 (a) IN GENERAL.—Section 1853(a)(3)(C)(ii) of the
21 Social Security Act (42 U.S.C. 1395w–23(c)(1)(C)(ii)) is
22 amended by inserting “and each subsequent year” after
23 “not more than 20 percent of such capitation rate in
24 2002”.

1 (b) EFFECTIVE DATE.—The amendment made by
 2 this section shall take effect on the date of enactment of
 3 this Act.

4 **TITLE IV—MEDICARE BENE-**
 5 **FICIARY OUTREACH AND**
 6 **EDUCATION**

7 **SEC. 401. MEDICARE CONSUMER COALITIONS.**

8 Title XXII of the Social Security Act (as added by
 9 section 101) is amended by adding at the end the following
 10 new part:

11 “PART C—MEDICARE CONSUMER COALITIONS

12 “ESTABLISHMENT OF MEDICARE CONSUMER COALITIONS

13 “SEC. 2281. (a) ESTABLISHMENT OF MEDICARE
 14 CONSUMER COALITIONS.—The Commissioner of the Com-
 15 petitive Medicare Agency (in this part referred to as the
 16 ‘Commissioner’) may establish Medicare Consumer Coali-
 17 tions (as defined in subsection (b)) to conduct information
 18 programs described in subsection (e).

19 “(b) MEDICARE CONSUMER COALITION DEFINED.—
 20 In this section, the term ‘Medicare Consumer Coalition’
 21 means an entity that is a nonprofit organization operated
 22 under the direction of a board of directors that is pri-
 23 marily composed of eligible beneficiaries.

24 “(c) REQUEST FOR PROPOSALS; SELECTION OF
 25 MEDICARE CONSUMER COALITIONS.—If the Commis-

1 sioner elects to establish Medicare Consumer Coalitions
2 under subsection (a), the Commissioner shall—

3 “(1) develop and disseminate a request for pro-
4 posals to establish Medicare Consumer Coalitions in
5 such areas as the Commissioner determines appro-
6 priate to assist in conducting the information pro-
7 grams described in subsection (a); and

8 “(2) select a proposal to establish a Medicare
9 Consumer Coalition to conduct the information pro-
10 grams in each such area.

11 “(d) PAYMENT TO MEDICARE CONSUMER COALI-
12 TIONS.—The Commissioner shall pay to each Medicare
13 Consumer Coalition for which a proposal has been selected
14 under subsection (c)(2) an amount equal to the sum of
15 any costs incurred—

16 “(1) in conducting the information programs
17 under subsection (e); and

18 “(2) in the hiring of staff to conduct the infor-
19 mation programs under such subsection.

20 “(e) INFORMATION PROGRAMS.—The information
21 programs described in this subsection are those activities
22 that are the responsibilities of the Commissioner under
23 clause (iii) of section 2202(a)(4) (relating to dissemination
24 of information), clause (iv) of such section (relating to dis-
25 semination of appeals rights information), and clause (v)

1 of such section (relating to beneficiary education pro-
 2 grams). If the Commissioner selects a Medicare Consumer
 3 Coalition to conduct such programs, the programs shall
 4 include the following:

5 “(1) CONTENTS.—A comparison among the
 6 original fee-for-service program under parts A and B
 7 of title XVIII, available Medicare+Choice plans
 8 under part C of such title, and available Medicare
 9 Prescription Plus plans under part B as follows:

10 “(A) BENEFITS.—A comparison of the
 11 benefits provided under each plan and program.

12 “(B) QUALITY AND PERFORMANCE.—The
 13 quality and performance of each plan and pro-
 14 gram.

15 “(C) BENEFICIARY COSTS.—The costs to
 16 eligible beneficiaries enrolled under each plan
 17 and program.

18 “(D) CONSUMER SATISFACTION SUR-
 19 VEYS.—The results of consumer satisfaction
 20 surveys regarding each plan and program.

21 “(E) ADDITIONAL INFORMATION.—Such
 22 additional information as the Commissioner
 23 may prescribe.

24 “(2) INFORMATION STANDARDS.—If the Com-
 25 missioner establishes Medicare Consumer Coalitions,

1 the Commissioner shall develop standards to ensure
2 that the information provided to eligible beneficiaries
3 under the information programs is complete, accu-
4 rate, and uniform.

5 “(3) REVIEW OF INFORMATION.—

6 “(A) IN GENERAL.—Subject to subpara-
7 graph (B), the Commissioner may prescribe the
8 procedures and conditions under which a Medi-
9 care Consumer Coalition may disseminate infor-
10 mation to eligible beneficiaries to ensure the co-
11 ordination of Federal, State, and local outreach
12 efforts to eligible beneficiaries.

13 “(B) DEADLINE.—Any information pro-
14 posed to be furnished to eligible beneficiaries
15 under this section shall be submitted to the
16 Commissioner not later than 45 days before the
17 date on which the information is to be dissemi-
18 nated to such beneficiaries.

19 “(4) CONSULTATION.—In order to conduct the
20 information programs under subsection (a), Medi-
21 care Consumer Coalitions may consult with the Ad-
22 ministrator of the Health Care Financing Adminis-
23 tration, entities that offer Medicare+Choice plans,
24 Medicare Prescription Plus plans, and public and
25 private purchasers of health care benefits.

1 “(f) REPORT.—If the Commissioner establishes
2 Medicare Consumer Coalitions under this section, not
3 later than December 31, 2003, the Commissioner shall
4 submit to the appropriate committees of Congress a report
5 on the performance of any Medicare Consumer Coalitions,
6 including an assessment of the effectiveness of the out-
7 reach efforts conducted under this section.

8 “(g) AUTHORIZATION OF APPROPRIATIONS.—There
9 are authorized to be appropriated to carry out this section
10 such sums as may be necessary.

11 “(h) EFFECTIVE DATE.—If the Commissioner estab-
12 lishes Medicare Consumer Coalitions, the Commissioner
13 should establish the such Coalitions under this section in
14 a manner that ensures that the information programs con-
15 ducted by Medicare Consumer Coalitions begin not later
16 than January 1, 2003.”.

○

CMS LIBRARY



3 8095 00010357 8